JPH1143460A - Phenyl-substituted hydroxycyclopentenone analogue - Google Patents
Phenyl-substituted hydroxycyclopentenone analogueInfo
- Publication number
- JPH1143460A JPH1143460A JP9201841A JP20184197A JPH1143460A JP H1143460 A JPH1143460 A JP H1143460A JP 9201841 A JP9201841 A JP 9201841A JP 20184197 A JP20184197 A JP 20184197A JP H1143460 A JPH1143460 A JP H1143460A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- phenyl
- formula
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 Phenyl-substituted hydroxycyclopentenone Chemical class 0.000 title claims abstract description 59
- 150000001875 compounds Chemical class 0.000 claims abstract description 65
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 24
- 230000011164 ossification Effects 0.000 claims abstract description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 229910000085 borane Inorganic materials 0.000 abstract description 3
- 239000003054 catalyst Substances 0.000 abstract description 3
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 125000001979 organolithium group Chemical group 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- ALOQTNHQNMYBDE-UHFFFAOYSA-N 1-bromo-4-methoxybutane Chemical compound COCCCCBr ALOQTNHQNMYBDE-UHFFFAOYSA-N 0.000 description 5
- 208000020084 Bone disease Diseases 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- QBLISOIWPZSVIK-UHFFFAOYSA-N 4-bromobutoxybenzene Chemical compound BrCCCCOC1=CC=CC=C1 QBLISOIWPZSVIK-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 3
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- FYGNJYLXDRROPN-UHFFFAOYSA-N [2-(4-phenylmethoxyphenyl)-1,3-thiazol-4-yl]methanamine Chemical compound NCC1=CSC(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)=N1 FYGNJYLXDRROPN-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- CXMYOMKBXNPDIW-UHFFFAOYSA-N cyclopenten-1-ylbenzene Chemical compound C1CCC=C1C1=CC=CC=C1 CXMYOMKBXNPDIW-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- RHDYQUZYHZWTCI-UHFFFAOYSA-N 1-methoxy-4-phenylbenzene Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=C1 RHDYQUZYHZWTCI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VDTUJQCSPFYIKZ-UHFFFAOYSA-N 4-methoxybut-1-ene Chemical compound COCCC=C VDTUJQCSPFYIKZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GENJFIIMXROHFK-UHFFFAOYSA-N C1C(C=C(C1=O)C2=CC=CC=C2Br)O Chemical compound C1C(C=C(C1=O)C2=CC=CC=C2Br)O GENJFIIMXROHFK-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- PUSCUDFKJQDKEF-UHFFFAOYSA-N [Ca].CC1=CC=CC=C1O Chemical compound [Ca].CC1=CC=CC=C1O PUSCUDFKJQDKEF-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ZDQWVKDDJDIVAL-UHFFFAOYSA-N catecholborane Chemical compound C1=CC=C2O[B]OC2=C1 ZDQWVKDDJDIVAL-UHFFFAOYSA-N 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- XNYOSXARXANYPB-UHFFFAOYSA-N dicyclohexylborane Chemical compound C1CCCCC1BC1CCCCC1 XNYOSXARXANYPB-UHFFFAOYSA-N 0.000 description 1
- YNLAOSYQHBDIKW-UHFFFAOYSA-M diethylaluminium chloride Chemical compound CC[Al](Cl)CC YNLAOSYQHBDIKW-UHFFFAOYSA-M 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 1
- HXJFQNUWPUICNY-UHFFFAOYSA-N disiamylborane Chemical compound CC(C)C(C)BC(C)C(C)C HXJFQNUWPUICNY-UHFFFAOYSA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000006197 hydroboration reaction Methods 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- DASUJKKKKGHFBF-UHFFFAOYSA-L thallium(i) carbonate Chemical compound [Tl+].[Tl+].[O-]C([O-])=O DASUJKKKKGHFBF-UHFFFAOYSA-L 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は骨粗鬆症、骨形成不
全症、骨損傷、歯槽骨異常等の骨疾患の予防剤または治
療剤に関する。TECHNICAL FIELD The present invention relates to a preventive or therapeutic agent for bone diseases such as osteoporosis, osteogenesis imperfecta, bone damage, and alveolar bone abnormality.
【0002】[0002]
【従来の技術】骨疾患には骨粗鬆症、骨形成不全症、骨
損傷、歯槽骨異常等が挙げられる。外見的には変化が起
きてないようにみえる骨は、骨芽細胞による骨形成と破
骨細胞による骨吸収が均等に保たれながら代謝を繰り返
しており、そのバランスが加齢や薬物等によって崩壊す
ることにより骨疾患が誘発される。例えば、骨粗鬆症は
骨吸収が骨形成を上回ることによる骨減少症である。骨
形成不全症や骨損傷は関節炎に伴う場合、或いは遺伝、
事故、薬物等による骨形成不全である。歯槽骨異常は歯
周病による炎症性の歯槽骨減少である。2. Description of the Related Art Bone diseases include osteoporosis, osteogenesis imperfecta, bone damage, and alveolar bone abnormalities. Bone that does not appear to have changed in appearance is repeatedly metabolized while maintaining bone formation by osteoblasts and bone resorption by osteoclasts evenly, and the balance is disrupted by aging or drugs etc. Doing so induces bone disease. For example, osteoporosis is osteopenia due to bone resorption exceeding bone formation. Osteogenesis imperfecta or bone damage is associated with arthritis,
Insufficient bone formation due to accidents, drugs, etc. Alveolar bone abnormalities are inflammatory alveolar bone loss due to periodontal disease.
【0003】従来、骨粗鬆症の治療剤は骨吸収抑制を主
作用とするものが中心であり、例えばエストロジェン、
活性型ビタミンD3、カルシトニン、ジホスホン酸等を
挙げることができる。しかし、これらの薬剤は、薬効と
副作用の分離が十分でない、或いは投与形態が不便であ
る等の問題がある。また、骨粗鬆症の本質からすると治
療剤としては骨形成促進を主作用とするものが重要と考
えられるが、現在骨形成促進を主作用とする治療剤は実
用化に至っていない。一方、その他の骨疾患である骨形
成不全症、骨損傷、歯槽骨異常等に対する治療剤につい
ては見出されていない。[0003] Conventionally, therapeutic agents for osteoporosis mainly have a main effect of inhibiting bone resorption, and for example, estrogen,
Active vitamin D 3 , calcitonin, diphosphonic acid and the like can be mentioned. However, these drugs have problems such as insufficient separation of drug efficacy and side effects, or inconvenient administration form. Also, considering the nature of osteoporosis, it is considered that a therapeutic agent having a main effect of promoting bone formation is important as a therapeutic agent. However, a therapeutic agent having a main effect of promoting bone formation has not yet been put to practical use. On the other hand, no therapeutic agent has been found for other bone diseases such as osteogenesis imperfecta, bone damage, alveolar bone abnormality and the like.
【0004】[0004]
【発明が解決しようとする課題】本発明の目的は、骨形
成促進作用を有する新規化合物を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a novel compound having a bone formation promoting action.
【0005】[0005]
【課題を解決するための手段】本発明者らは鋭意研究を
進めた結果、ある種のフェニル置換ヒドロキシシクロペ
ンテノン類縁体およびその製薬学的に許容される塩を有
効成分とする医薬組成物が上記目的を達成できることを
見出し、本発明を完成した。Means for Solving the Problems As a result of diligent studies by the present inventors, a pharmaceutical composition comprising a certain phenyl-substituted hydroxycyclopentenone analog and a pharmaceutically acceptable salt thereof as an active ingredient Found that the above object could be achieved, and completed the present invention.
【0006】すなわち、本発明は、式(I)That is, the present invention relates to a compound of the formula (I)
【0007】[0007]
【化2】 Embedded image
【0008】[式中、R1はハロゲン原子または式 −(CH2)mY1 n(CH2)pR3 {式中、Y1は酸素原子または硫黄原子を示し、R3は水
素原子または式 −CO2R4 (式中、R4は水素原子、炭素数1〜5のアルキル基ま
たは炭素数2〜6のアルケニル基を示す。)で表される
基を示し、nは0または1を示し、m,pはそれぞれ0
〜5の整数を示す。}で表される基を示し、R2は式 −(CH2)qY2 rR5 (式中、Y2は酸素原子または硫黄原子を示し、R5は水
素原子、炭素数1〜5のアルキル基、炭素数2〜6のア
ルケニル基、炭素数2〜6のアルキニル基、炭素数3〜
7のシクロアルキル基またはアリール基を示し、rは0
または1を示し、qは0〜5の整数を示す。)で表され
る基を示し、Xは水素原子または水酸基を示す。]で表
されるフェニル置換ヒドロキシシクロペンテノン類縁体
またはその製薬学的に許容される塩である。Wherein R 1 is a halogen atom or a formula — (CH 2 ) m Y 1 n (CH 2 ) p R 3 , wherein Y 1 represents an oxygen atom or a sulfur atom, and R 3 represents a hydrogen atom or (wherein, R 4 is a hydrogen atom, an alkyl group or an alkenyl group having 2 to 6 carbon atoms of 1 to 5 carbon atoms.) wherein -CO 2 R 4 represents a group represented by, n represents 0 or 1 and m and p are each 0
Represents an integer of from 5 to 5. Wherein R 2 is a group represented by the formula — (CH 2 ) q Y 2 r R 5 (wherein Y 2 represents an oxygen atom or a sulfur atom, R 5 is a hydrogen atom, and has 1 to 5 carbon atoms). Alkyl group, alkenyl group having 2 to 6 carbon atoms, alkynyl group having 2 to 6 carbon atoms,
7 represents a cycloalkyl group or an aryl group, and r represents 0
Or 1 and q represents an integer of 0 to 5; ), And X represents a hydrogen atom or a hydroxyl group. A phenyl-substituted hydroxycyclopentenone analog or a pharmaceutically acceptable salt thereof.
【0009】また、本発明は一般式(I)に示される化
合物もしくはその製薬学的に許容される塩を含有するこ
とを特徴とする医薬組成物または骨形成促進剤である。Further, the present invention is a pharmaceutical composition or an osteogenesis promoter containing the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof.
【0010】本発明におけるハロゲン原子とは、フッ素
原子、塩素原子、臭素原子、ヨウ素原子であり、炭素数
1〜5のアルキル基とは、直鎖状または分枝鎖状のもの
をいい、例えばメチル基、エチル基、プロピル基、イソ
プロピル基、ブチル基、ペンチル基等であり、炭素数2
〜6のアルケニル基とは、直鎖状または分枝鎖状のもの
をいい、例えばビニル基、アリル基、2−ブテニル基、
3−メチル−2−ブテニル基等である。本発明における
炭素数2〜6のアルキニル基とは、直鎖状または分枝鎖
状のものをいい、例えばエチニル基、プロピニル基、2
−プロピニル基、ブチニル基、2−ブチニル基、2−ペ
ンチニル基等である。本発明における炭素数3〜7のシ
クロアルキル基とは、例えばシクロプロピル基、シクロ
ブチル基、シクロペンチル基、シクロヘキシル基、シク
ロヘプチル基等である。本発明におけるアリール基と
は、フェニル基または置換されたフェニル基であり、こ
こで示す置換基とは炭素数1〜4のアルキル基、炭素数
1〜4のアルコキシ基等である。具体例としては、例え
ばフェニル基、トリル基、メトキシフェニル基等であ
る。In the present invention, the halogen atom is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and the alkyl group having 1 to 5 carbon atoms means a linear or branched one. A methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a pentyl group, etc.
The alkenyl group of ~ 6 means a linear or branched one, for example, a vinyl group, an allyl group, a 2-butenyl group,
3-methyl-2-butenyl group and the like. The alkynyl group having 2 to 6 carbon atoms in the present invention means a linear or branched alkynyl group such as an ethynyl group, a propynyl group,
-Propynyl, butynyl, 2-butynyl, 2-pentynyl and the like. The cycloalkyl group having 3 to 7 carbon atoms in the present invention is, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and the like. The aryl group in the present invention is a phenyl group or a substituted phenyl group, and the substituent shown here is an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, and the like. Specific examples include a phenyl group, a tolyl group, and a methoxyphenyl group.
【0011】式(I)の化合物は、例えば以下の反応式
に要約する方法により製造できる。The compounds of formula (I) can be prepared, for example, by the methods outlined in the following reaction schemes.
【0012】 [0012]
【0013】(反応式中、R6はハロゲン原子またはト
リフルオロメタンスルフォキシ基を示し、R7は水酸基
の保護基を示し、X2は水素原子または式 −OR7 で表される基を示し、X3は水素原子、ハロゲン原子ま
たはトリ−n−ブチルスズを示し、R1、R2およびXは
前記と同意義である。) 上記反応式を説明すると、 (1)まず、THF中、フランをn−ブチルリチウムに
てリチオ化した後、必要に応じてジエチルアルミニウム
クロリドを反応させ、次いで式(II)で表される化合物
を反応させて式(III)の化合物を得る。反応温度は−
50℃〜室温、好ましくは−20〜0℃である。(In the reaction formula, R 6 represents a halogen atom or a trifluoromethanesulfoxy group, R 7 represents a hydroxyl-protecting group, X 2 represents a hydrogen atom or a group represented by the formula —OR 7. , X 3 represents a hydrogen atom, a halogen atom or tri-n-butyltin, and R 1 , R 2 and X have the same meanings as described above.) To explain the above reaction formula, (1) First, furan in THF Is lithiated with n-butyllithium and, if necessary, reacted with diethylaluminum chloride, followed by reaction with the compound represented by the formula (II) to obtain a compound of the formula (III). The reaction temperature is-
The temperature is from 50C to room temperature, preferably from -20C to 0C.
【0014】(2)式(III)の化合物は酸触媒存在下
加熱することで転位が起こり、式(IV)の化合物とな
り、水酸基を保護して式(V)の化合物に導く。(2) The compound of formula (III) undergoes rearrangement by heating in the presence of an acid catalyst to become a compound of formula (IV), which protects the hydroxyl group and leads to a compound of formula (V).
【0015】転位反応は、無溶媒または適当な溶媒中で
行うことができる。溶媒としては、水、あるいはエーテ
ル系(ジエチルエーテル、ジオキサン、テトラヒドロフ
ランなど)、ケトン系(アセトン、メチルイソブチルケ
トンなど)、エステル系(酢酸エチルなど)、脂肪族炭
化水素系(ヘキサン、ヘプタン、シクロヘキサンなど)
または芳香族炭化水素系(ベンゼン、トルエン、ジクロ
ロベンゼンなど)の有機溶媒を単独または混合して用い
ることができる。好ましくは水とテトラヒドロフランの
混合溶媒である。The rearrangement reaction can be carried out without a solvent or in a suitable solvent. Examples of the solvent include water or ethers (such as diethyl ether, dioxane, and tetrahydrofuran), ketones (such as acetone and methyl isobutyl ketone), esters (such as ethyl acetate), and aliphatic hydrocarbons (such as hexane, heptane, and cyclohexane). )
Alternatively, an aromatic hydrocarbon (benzene, toluene, dichlorobenzene, etc.) organic solvent can be used alone or as a mixture. Preferred is a mixed solvent of water and tetrahydrofuran.
【0016】酸触媒としては、無機酸(塩酸、硫酸な
ど)あるいは有機酸(酢酸、トリフルオロ酢酸、p−ト
ルエンスルホン酸、メタンスルホン酸など)を式(II
I)で表される化合物に対し0.001〜100当量、
好ましくは0.01〜1当量用いる。反応温度は、0℃
〜溶媒の還流温度、好ましくは50〜100℃である。As the acid catalyst, an inorganic acid (such as hydrochloric acid or sulfuric acid) or an organic acid (such as acetic acid, trifluoroacetic acid, p-toluenesulfonic acid, or methanesulfonic acid) is represented by the formula (II)
0.001 to 100 equivalents to the compound represented by I),
Preferably, 0.01 to 1 equivalent is used. Reaction temperature is 0 ° C
To the reflux temperature of the solvent, preferably from 50 to 100 ° C.
【0017】水酸基の保護基(上記式中R7で示す)と
しては、例えば置換シリル基(トリメチルシリル基、ト
リエチルシリル基、tert−ブチルジメチルシリル
基、tert−ブチルジフェニルシリル基、フェニルジ
メチルシリル基など)、テトラヒドロピラニル基、テト
ラヒドロフラニル基、アルコキシアルキル基(メトキシ
メチル基、エトキシエチル基など)、ベンジルオキシメ
チル基、ベンジル基、トリチル基、アシル基(ホルミル
基、アセチル基、ベンゾイル基など)が挙げられる。Examples of the hydroxyl-protecting group (indicated by R 7 in the above formula) include, for example, substituted silyl groups (trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, phenyldimethylsilyl group, etc.) ), Tetrahydropyranyl, tetrahydrofuranyl, alkoxyalkyl (methoxymethyl, ethoxyethyl, etc.), benzyloxymethyl, benzyl, trityl, acyl (formyl, acetyl, benzoyl, etc.) No.
【0018】(3)式中、R1に対応する有機ボラン化
合物、塩基およびパラジウム触媒の存在下、式(V)で
表される化合物を反応させ式(VI)で表される化合物を
得る。(3) In the formula, the compound represented by the formula (V) is reacted in the presence of an organic borane compound corresponding to R 1 , a base and a palladium catalyst to obtain a compound represented by the formula (VI).
【0019】R1に対応する有機ボラン化合物は、例え
ばジシクロヘキシルボラン、ジシアミルボラン、カテコ
ールボラン、9−ボラビシクロ[3.3.1]ノナン、
テキシルボラン等とR1に対応するアルケンとのヒドロ
ホウ素化反応で得られ、式(V)で表される化合物に対
し1〜10当量、好ましくは1〜2当量用いる。Examples of the organic borane compound corresponding to R 1 include dicyclohexylborane, disiamylborane, catecholborane, 9-borabicyclo [3.3.1] nonane,
It is obtained by a hydroboration reaction between texylborane or the like and an alkene corresponding to R 1 , and is used in an amount of 1 to 10 equivalents, preferably 1 to 2 equivalents, relative to the compound represented by the formula (V).
【0020】塩基としては、例えばナトリウムエトキシ
ド、水酸化ナトリウム、水酸化カリウム、リン酸三カリ
ウム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸セシ
ウム、炭酸タリウムなどが挙げられ、式(V)で表され
る化合物に対し1〜10当量、好ましくは1〜2当量用
いる。Examples of the base include sodium ethoxide, sodium hydroxide, potassium hydroxide, tripotassium phosphate, sodium hydrogen carbonate, sodium carbonate, cesium carbonate, thallium carbonate and the like, and are represented by the formula (V). It is used in an amount of 1 to 10 equivalents, preferably 1 to 2 equivalents, based on the compound.
【0021】パラジウム触媒としては、例えば[1,
1’−ビス(ジフェニルホスフィノ)フェロセン]パラ
ジウムジクロリド・塩化メチレン錯体、トリス(ジベン
ジリデンアセトン)ジパラジウム(0)クロロホルム、
ビス(ジベンジリデンアセトン)パラジウム(0)、テ
トラキス(トリフェニルホスフィン)パラジウム
(0)、ビス(アセチルアセトナート)パラジウム(I
I)、ジクロロビス(ベンゾニトリル)パラジウム(I
I)などが挙げられ、式(V)で表される化合物に対し
0.001〜0.9当量、好ましくは0.01〜0.5
当量を用いる。As the palladium catalyst, for example, [1,
1′-bis (diphenylphosphino) ferrocene] palladium dichloride / methylene chloride complex, tris (dibenzylideneacetone) dipalladium (0) chloroform,
Bis (dibenzylideneacetone) palladium (0), tetrakis (triphenylphosphine) palladium (0), bis (acetylacetonato) palladium (I
I), dichlorobis (benzonitrile) palladium (I
I) and the like, and 0.001 to 0.9 equivalent, preferably 0.01 to 0.5 equivalent to the compound represented by the formula (V).
Use the equivalent.
【0022】反応溶媒としては、必要に応じて不活性有
機溶媒(例えばテトラヒドロフラン、ジオキサンなど)
を用いる。As the reaction solvent, if necessary, an inert organic solvent (eg, tetrahydrofuran, dioxane, etc.)
Is used.
【0023】反応温度は室温〜溶媒還流温度、好ましく
は50〜100℃である。The reaction temperature is from room temperature to the reflux temperature of the solvent, preferably from 50 to 100 ° C.
【0024】(4)式(VI)の化合物をエーテル中、t
ert−ブチルリチウムあるいはn−ブチルリチウムと
式(VII)の化合物とから調製した有機リチウム試薬と
反応させ、カラムクロマトグラフィーにて精製し、式
(VIIIa)および(VIIIb)の化合物を得る。(4) The compound of the formula (VI) is t
Reaction of tert-butyllithium or n-butyllithium with an organolithium reagent prepared from the compound of formula (VII) and purification by column chromatography give compounds of formula (VIIIa) and (VIIIb).
【0025】(5)式(VIIIa)の化合物の水酸基の保
護基を通常の方法を用いて脱保護を行い式(IX)の化合
物を得る。(5) The hydroxyl-protecting group of the compound of the formula (VIIIa) is deprotected by a conventional method to give the compound of the formula (IX).
【0026】(6)式(IX)の化合物を塩化メチレン、
クロロホルム、ベンゼンなどの不活性溶媒中、二酸化マ
ンガン、ピリジニウムクロロクロメート、ピリヂニウム
ジクロメートなどの酸化剤と反応させ式(I)の化合物
を得る。(6) A compound of the formula (IX) is methylene chloride,
Reaction with an oxidizing agent such as manganese dioxide, pyridinium chlorochromate, or pyridinium dichromate in an inert solvent such as chloroform or benzene gives the compound of formula (I).
【0027】上記各工程の生成物は、必要に応じて、そ
れ自体既知の方法により、例えば、シリカゲルカラムク
ロマトグラフィーなどの方法により反応混合物から分
離、精製することができる。The product of each of the above steps can be separated and purified from the reaction mixture, if necessary, by a method known per se, for example, by a method such as silica gel column chromatography.
【0028】本発明の化合物は、全身的または局所的に
経口または非経口的に慣用の投予剤型で投与することが
できる。これらは、例えば、通常の方法により製造する
ことができる錠剤、粉剤、顆粒剤、散剤、カプセル剤、
液剤、乳剤、懸濁剤等の形で経口投与することができ
る。更に、その溶液、乳剤、懸濁剤等を注射等により投
与することができる。また、コラーゲン・ゲル、コラー
ゲン膜、ガラス繊維膜、ハイドロキシアパタイト等の各
種坦体との混合体で局所に適応することができる。The compounds of the present invention can be administered systemically or topically orally or parenterally in conventional dosage forms. These are, for example, tablets, powders, granules, powders, capsules, which can be produced by ordinary methods.
It can be administered orally in the form of a solution, emulsion, suspension or the like. Further, the solution, emulsion, suspension and the like can be administered by injection or the like. In addition, it can be locally applied by a mixture with various carriers such as collagen gel, collagen membrane, glass fiber membrane, and hydroxyapatite.
【0029】投与量は年齢、体重、投与形態等により異
なるが、通常成人に対し0.0001〜10g/日であ
り、これを1日1回または数回に分けて投与する。The dosage varies depending on the age, body weight, dosage form, etc., but is usually 0.0001 to 10 g / day for an adult, and is administered once or several times a day.
【0030】[0030]
【発明の効果】本発明は優れた骨形成促進作用を示し、
骨粗鬆症、骨形成不全症、骨損傷、歯槽骨異常等の骨疾
患の予防薬または治療薬として有用である。Industrial Applicability The present invention shows an excellent bone formation promoting action,
It is useful as a preventive or therapeutic agent for bone diseases such as osteoporosis, osteogenesis imperfecta, bone damage, and alveolar bone abnormality.
【0031】以下、本発明の効果を試験例により具体的
に説明する。Hereinafter, the effects of the present invention will be specifically described with reference to test examples.
【0032】試験例 ヒト培養骨芽細胞は、腰原らの方法(in vitro cell. de
velop. biol.,第25巻,37-43頁、1989年)によって得ら
れたヒト長管骨骨膜片から樹立した。Test Example Human cultured osteoblasts were obtained by the method of Koshihara et al. (In vitro cell.
velop. biol., Vol. 25, pp. 37-43, 1989).
【0033】方法 骨芽細胞を22PDL(Population doubling levels)とな
るように96穴のプレートに播種し、増殖がコンフルエ
ントになった時、2mM-α-グリセロリン酸塩存在下で、
フェニル置換ヒドロキシシクロペンテノン誘導体を加
え、1日おきに培養液を変えて24日間培養した。この
細胞層を、Hank’s(0.1ml)溶液(pH7.
4)で洗浄した後、アルカリフォスファターゼ(AL
P)の合成基質であるρ−ニトロフェニルリン酸を溶解
したHank’s(0.1ml)溶液を加えた。5分間
室温で放置し、その反応液を採取し、ALP活性を測定
した。カルシウム量は細胞層を再び、Hank’s溶液
で洗浄し、冷5%過塩素酸(0.05ml)を加え、4
℃で15分間振とうしてカルシウムを抽出し、発色法で
定量した。Method The osteoblasts were seeded on a 96-well plate at 22 PDL (Population doubling levels). When the growth reached confluence, the cells were cultured in the presence of 2 mM α-glycerophosphate.
A phenyl-substituted hydroxycyclopentenone derivative was added, and the culture was changed every other day and cultured for 24 days. This cell layer was washed with Hank's (0.1 ml) solution (pH 7.
After washing with 4), alkaline phosphatase (AL
A Hank's (0.1 ml) solution in which ρ-nitrophenyl phosphate, which is a synthetic substrate of P), was dissolved was added. The mixture was allowed to stand at room temperature for 5 minutes, the reaction solution was collected, and ALP activity was measured. The amount of calcium was determined by washing the cell layer again with Hank's solution and adding cold 5% perchloric acid (0.05 ml).
Calcium was extracted by shaking at 15 ° C for 15 minutes and quantified by a color development method.
【0034】ALP活性の測定 MarioとCarliの方法(Nature, 第196卷、600−
601頁、1962年)を用いて行った。採取した反応液の
410nmの吸光度を測定した。Measurement of ALP activity The method of Mario and Carli (Nature, vol. 196, 600-
601, 1962). The absorbance at 410 nm of the collected reaction solution was measured.
【0035】カルシウムの測定 オルトクレゾールフタレインコンプレキソン(OCPC
法)(Anal. Biochem. 第18卷、520-531頁、1967
年)に基づいたキット(カルシウムCテストワコー)を
用いて行った。抽出液5μlと緩衝液250μlを混合
した後、発色液(OCPC 0.4mg/ml、8−キ
ノリノール含有)25μlを加えてよく混和した後、5
70nmの吸光度を測定した。Determination of calcium orthocresol phthalein complexone (OCPC
Method) (Anal. Biochem. Vol. 18, pp. 520-531, 1967)
Year), using a kit (Calcium C Test Wako). After 5 μl of the extract and 250 μl of the buffer were mixed, 25 μl of a coloring solution (OCPC 0.4 mg / ml, containing 8-quinolinol) was added and mixed well.
The absorbance at 70 nm was measured.
【0036】この結果を表1に示す。Table 1 shows the results.
【0037】[0037]
【表1】 [Table 1]
【0038】注)表中の化合物1および2は、後記実施
例で製造した化合物である。被験化合物はエタノール溶
液とし、コントロールは溶媒処理群として比較を行っ
た。Note) Compounds 1 and 2 in the table are compounds produced in the following Examples. The test compound was an ethanol solution, and the control was a solvent-treated group for comparison.
【0039】以上の結果、化合物1または2の添加によ
り骨形成マーカーであるALP活性の上昇および骨芽細
胞の石灰化促進がみられ、強い骨形成促進活性が観察さ
れた。As a result, the addition of Compound 1 or 2 increased the ALP activity as a bone formation marker and promoted calcification of osteoblasts, and a strong bone formation promoting activity was observed.
【0040】[0040]
【実施例】以下、参考例および実施例を挙げて本発明を
さらに詳細に説明するが、本発明はこれらの記載によっ
てなんら制限されるものではない。EXAMPLES Hereinafter, the present invention will be described in more detail with reference to Reference Examples and Examples, but the present invention is not limited by these descriptions.
【0041】参考例1(4R*,5S*)−5−(2−ブロモフェニル)−4−
(tertーブチルジメチルシロキシ)−2−シクロペ
ンテン−1−オン (1)フラン(58.6ml,806mmol)のTH
F(540ml)溶液に−78℃でn−BuLi(29
6ml,739mmol, 2.5M ヘキサン溶液)を
滴下した後、−20℃で1.5時間攪拌した。−20℃
で2−ブロモベンズアルデヒド(124.4g,672
mmol)のTHF(20ml)溶液を加え、室温に1
時間かけて昇温した。反応液に飽和塩化アンモニウム水
溶液(600ml)を加えた後、酢酸エチル(250m
l)で抽出した。得られた有機層を硫酸マグネシウムで
乾燥した後、濾過した。濾液を減圧下濃縮して化合物
(2−ブロモフェニル)フリルメタノールの粗生成物
(186.7g)を得た。得られた粗生成物をそのまま
次の反応に用いた。Reference Example 1 (4R * , 5S * )-5- (2-bromophenyl) -4-
(Tert-butyldimethylsiloxy) -2-cyclope
TH of 1 -one-one (1) furan (58.6 ml, 806 mmol)
F (540 ml) solution at -78 ° C with n-BuLi (29
6ml, 739mmol, 2.5M hexane solution) was added dropwise, and the mixture was stirred at -20 ° C for 1.5 hours. -20 ° C
With 2-bromobenzaldehyde (124.4 g, 672
mmol) in THF (20 ml).
The temperature was raised over time. A saturated aqueous ammonium chloride solution (600 ml) was added to the reaction solution, and then ethyl acetate (250 m
Extracted in l). The obtained organic layer was dried over magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain a crude product (186.7 g) of the compound (2-bromophenyl) furylmethanol. The obtained crude product was directly used for the next reaction.
【0042】前の反応で得られた(2−ブロモフェニ
ル)フリルメタノールの粗生成物(186.7g)のT
HF(1680ml)および水(280ml)溶液にp
−トルエンスルホン酸一水和物(8.11g,47.1
mmol)を加え、80℃で15時間攪拌した。室温に
冷却後、反応液を約半量まで濃縮し、飽和重曹水溶液
(600ml)を加えて中和した後、酢酸エチル(50
0ml)で抽出した。得られた有機層を硫酸マグネシウ
ムで乾燥した後、濾過した。濾液を減圧下濃縮して得ら
れた粗生成物をシリカゲルカラムクロマトグラフィーで
精製後、再結晶(酢酸エチル−ヘキサン)して、(4R
*,5S*)−5−(2−ブロモフェニル)−4−ヒドロ
キシ−2−シクロペンテン−1−オン(127.5g)
を収率75%で得た。The crude product of (2-bromophenyl) furylmethanol (186.7 g) obtained in the previous reaction
Add HF (1680 ml) and water (280 ml) solution to p
-Toluenesulfonic acid monohydrate (8.11 g, 47.1)
mmol) and stirred at 80 ° C. for 15 hours. After cooling to room temperature, the reaction solution was concentrated to about half the volume, neutralized by adding a saturated aqueous sodium bicarbonate solution (600 ml), and then ethyl acetate (50
0 ml). The obtained organic layer was dried over magnesium sulfate and then filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography, and then recrystallized (ethyl acetate-hexane) to give (4R
* , 5S * )-5- (2-Bromophenyl) -4-hydroxy-2-cyclopenten-1-one (127.5 g).
Was obtained in a yield of 75%.
【0043】m.p. 92.3−93.0℃ (無色
プリズム晶、酢酸エチル−ヘキサンより再結晶)1 H−NMR(CDCl3,200MHz)δppm;
1.68(br s,1H),3.87(d,J=3.
0Hz,1H),5.04−5.18(m,1H),
6.43(dd,J=5.8,1.4Hz,1H),
7.02−7.38(m,4H),7.53−7.71
(m,1H) IR(neat):3418,3060,2900,1
694,1588,1568,1472,1440,1
344,1190,1162,1108,1048,9
78,940,906,886,754,684,66
4,638,558,492,444 cm-1 MS(EI)m/z:252(M+)。M. p. 92.3-93.0 ° C. (colorless prisms, recrystallized from ethyl acetate-hexane) 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
1.68 (br s, 1H), 3.87 (d, J = 3.
0 Hz, 1H), 5.04-5.18 (m, 1H),
6.43 (dd, J = 5.8, 1.4 Hz, 1H),
7.02-7.38 (m, 4H), 7.53-7.71
(M, 1H) IR (neat): 3418, 3060, 2900, 1
694, 1588, 1568, 1472, 1440, 1
344, 1190, 1162, 1108, 1048, 9
78,940,906,886,754,684,66
4,638,558,492,444 cm -1 MS (EI) m / z: 252 (M + ).
【0044】(2)10℃で(4R*,5S*)−5−
(2−ブロモフェニル)−4−ヒドロキシ−2−シクロ
ペンテン−1−オン(11.16g、44.1mmo
l)の塩化メチレン(88.2ml)溶液にtert−
ブチルジメチルシリルクロリド(9.97g、66.1
mmol)とイミダゾール(4.20g,61.7mm
ol)を加え、室温で1時間攪拌した。反応液に飽和重
曹水溶液(300ml)を加えた後、ヘキサン(100
ml×2)で抽出した。得られた有機層を硫酸マグネシ
ウムで乾燥した後、濾過した。濾液を減圧下濃縮して得
られた粗精製物をシリカゲルカラムクロマトグラフィー
で精製して標記化合物(13.2g)を収率82%で得
た。(2) At 10 ° C., (4R * , 5S * )-5
(2-Bromophenyl) -4-hydroxy-2-cyclopenten-1-one (11.16 g, 44.1 mmol)
l) in methylene chloride (88.2 ml) solution
Butyldimethylsilyl chloride (9.97 g, 66.1)
mmol) and imidazole (4.20 g, 61.7 mm)
ol) and stirred at room temperature for 1 hour. After adding a saturated aqueous solution of sodium bicarbonate (300 ml) to the reaction mixture,
ml × 2). The obtained organic layer was dried over magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure, and the crude product obtained was purified by silica gel column chromatography to give the title compound (13.2 g) in 82% yield.
【0045】1H−NMR(CDCl3,200MHz)
δppm;−0.12(s,3H),−0.07(s,
3H),0.86(s,9H),3.72−3.83
(m,1H),5.09−5.16(m,1H),6.
33(dd,J=5.8,1.3Hz,1H),7.0
1−7.34(m,3H),7.47(dd,J=5.
8,2.0Hz,1H),7.53−7.62(m,1
H) IR(neat):2955,2930,2886,2
858,1724,1591,1569,1473,1
441,1389,1362,1255,1202,1
156,1117,1080,1026,1008,9
86,940,839,779,752,671,63
7,559 cm-1 MS(CI)m/z:366(MH+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; -0.12 (s, 3H), -0.07 (s,
3H), 0.86 (s, 9H), 3.72-3.83.
(M, 1H), 5.09-5.16 (m, 1H), 6.
33 (dd, J = 5.8, 1.3 Hz, 1H), 7.0
1-7.34 (m, 3H), 7.47 (dd, J = 5.
8, 2.0 Hz, 1 H), 7.53-7.62 (m, 1
H) IR (neat): 2955, 2930, 2886, 2
858, 1724, 1591, 1569, 1473, 1
441, 1389, 1362, 1255, 1202, 1
156,1117,1080,1026,1008,9
86,940,839,779,752,671,63
7,559 cm -1 MS (CI) m / z: 366 (MH <+> ).
【0046】参考例2(4R*,5S*)−5−フェニル−4−(tertーブ
チルジメチルシロキシ )−2−シクロペンテン−1−オ
ン 参考例1において、2−ブロモベンズアルデヒドの代わ
りに、ベンズアルデヒドを用い、実質的に参考例1と同
様にして標記化合物を得た。Reference Example 2 (4R * , 5S * )-5-phenyl-4- (tert-butyl
Tyldimethylsiloxy ) -2-cyclopentene-1-o
In Reference Example 1, the title compound was obtained in substantially the same manner as in Reference Example 1, except that benzaldehyde was used instead of 2-bromobenzaldehyde.
【0047】1H−NMR(CDCl3,200MHz)
δppm;−0.18(s,3H),−0.14(s,
3H),0.77(s,9H),3.33(d,J=
2.6Hz,1H),4.80−4.84(m,1
H),6.21(d,J=5.7Hz,1H),6.9
4−7.03(m,2H),7.11−7.30(m,
3H),7.43 (dd,J=5.7,1.5Hz,
1H) IR(neat): 3065,3032,2955,
2930,2886,2858,1722,1605,
1497,1472,1464,1407,1389,
1362,1302,1255,1200,1121,
1084,1046,1007, 986,939,8
38,778,699,669,639,551 cm
-1 MS(FAB)m/z:289(MH+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; -0.18 (s, 3H), -0.14 (s,
3H), 0.77 (s, 9H), 3.33 (d, J =
2.6 Hz, 1H), 4.80-4.84 (m, 1
H), 6.21 (d, J = 5.7 Hz, 1H), 6.9.
4-7.03 (m, 2H), 7.11-7.30 (m,
3H), 7.43 (dd, J = 5.7, 1.5 Hz,
1H) IR (neat): 3065, 3032, 2955,
2930, 2886, 2858, 1722, 1605
1497, 1472, 1464, 1407, 1389,
1362, 1302, 1255, 1200, 1121,
1084, 1046, 1007, 986, 939, 8
38,778,699,669,639,551 cm
-1 MS (FAB) m / z: 289 (MH <+> ).
【0048】実施例1(4R*,5R*)−4−ヒドロキシ−4−(4−メトキ
シ−1−ブチル)−5−[2−(3−メトキシカルボニ
ル−1−プロピル)フェニル]−2−シクロペンテン−
1−オン (化合物1) (1)0℃でメチル 3−ブテノエート(1.66g、
16.6mmol)に9−BBN(30.2ml、1
5.3mmol,0.5N THF溶液)を加え、室温
で一昼夜攪拌した。反応液に参考例1で得た(4R*,
5S*)−4−(tert−ブチルジメチルシロキシ)
−5−(2−ブロモフェニル)−2−シクロペンテン−
1−オン(4.67g,12.7mmol),K3PO4
(3.24g,15.3mmol)および[1,1’−
ビス(ジフェニルホスフィノ)フェロセン]パラジウム
ジクロリド・塩化メチレン錯体(311mg,0.38
mmol)を加え3時間加熱還流した。室温まで冷却
後、反応液に飽和塩化アンモニウム水溶液(50ml)
を加え、ヘキサン(30ml×2)で抽出した。得られ
た有機層を硫酸マグネシウムで乾燥した後、濾過した。
濾液を減圧下濃縮して得られた粗精製物をシリカゲルカ
ラムクロマトグラフィーで精製して化合物 (4R*,5
S*)−4−(tert−ブチルジメチルシロキシ)−
5−[2−(3−メトキシカルボニル−1−プロピル)
フェニル]−2−シクロペンテン−1−オン(2.97
g)を収率63%で得た。Example 1 (4R * , 5R * )-4-hydroxy-4- (4-methoxy)
C-1-butyl) -5- [2- (3-methoxycarbonyl)
Ru-1-propyl) phenyl] -2-cyclopentene-
1-one (Compound 1) (1) Methyl 3-butenoate (1.66 g,
16.6 mmol) in 9-BBN (30.2 ml, 1
(5.3 mmol, 0.5N THF solution) and stirred at room temperature for 24 hours. The reaction solution obtained in Reference Example 1 (4R * ,
5S * )-4- (tert-butyldimethylsiloxy)
-5- (2-bromophenyl) -2-cyclopentene-
1-one (4.67 g, 12.7 mmol), K 3 PO 4
(3.24 g, 15.3 mmol) and [1,1′-
Bis (diphenylphosphino) ferrocene] palladium dichloride / methylene chloride complex (311 mg, 0.38
mmol) and heated under reflux for 3 hours. After cooling to room temperature, a saturated ammonium chloride aqueous solution (50 ml) was added to the reaction solution.
And extracted with hexane (30 ml × 2). The obtained organic layer was dried over magnesium sulfate and then filtered.
The crude product obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography to obtain the compound (4R * , 5
S * )-4- (tert-Butyldimethylsiloxy)-
5- [2- (3-methoxycarbonyl-1-propyl)
Phenyl] -2-cyclopenten-1-one (2.97
g) was obtained with a yield of 63%.
【0049】1H−NMR(CDCl3,300MHz)
δppm;−0.14(s,3H),−0.05(s,
3H),0.85(s,9H),1.10−1.99
(m,2H),2.37(t,J=7.5Hz,2
H),2.47−2.82(m,2H),3.67
(s,3H),3.74(d,J=2.8Hz,1
H),4.88−4.93(m,1H),6.32(d
d,J=5.8,1.2Hz,1H),6.80−6.
87(m,1H),7.10−7.35(m,3H),
7.53(dd,J=5.8,2.1Hz,1H) IR(neat):3063,2929,2858,1
723,1494,1471,1451,1436,1
413,1388,1362,1329,1300,1
253,1199,1167,1119,1074,1
007,985,940,891,841,779,7
54,674,638,557 cm-1 MS(CI)m/z:389(MH+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; -0.14 (s, 3H), -0.05 (s,
3H), 0.85 (s, 9H), 1.10-1.99
(M, 2H), 2.37 (t, J = 7.5 Hz, 2
H), 2.47-2.82 (m, 2H), 3.67.
(S, 3H), 3.74 (d, J = 2.8 Hz, 1
H), 4.88-4.93 (m, 1H), 6.32 (d
d, J = 5.8, 1.2 Hz, 1H), 6.80-6.
87 (m, 1H), 7.10-7.35 (m, 3H),
7.53 (dd, J = 5.8, 2.1 Hz, 1H) IR (neat): 3063, 2929, 2858, 1
723, 1494, 1471, 1451, 1436, 1
413, 1388, 1362, 1329, 1300, 1
253,1199,1167,1119,1074,1
007,985,940,891,841,779,7
54,674,638,557 cm- 1 MS (CI) m / z: 389 (MH <+> ).
【0050】(2)−78℃で4−ブロモ−1−メトキ
シブタン(2.17g,13.1mmol)のエ−テル
(65ml)溶液にt−ブチルリチウム(9.5ml、
20.1mmol,2.13Mのペンタン溶液)を加え、−
78℃で1時間攪拌した。−100℃で上記(1)で得
た化合物(3.91g、10.1mmol)のエ−テル
(10ml)溶液を加え、−50℃まで3時間かけて昇
温した。反応液に飽和塩化アンモニウム水溶液(100
ml)を加え、ヘキサン(50ml×2)で抽出した。
得られた有機層を硫酸マグネシウムで乾燥した後、濾過
した。濾液を減圧下濃縮して得られた粗精製物をシリカ
ゲルカラムクロマトグラフィーで精製して化合物 (3
RS,4S*,5R*)−3−ヒドロキシ−3−(4−メ
トキシ−1−ブチル)−4−[2−(3−メトキシカル
ボニル−1−プロピル)フェニル]−5−(tert−
ブチルジメチルシロキシ)−1−シクロペンテン(1.
68g)を収率35%で得た。(2) A solution of 4-bromo-1-methoxybutane (2.17 g, 13.1 mmol) in ether (65 ml) at -78 ° C. was t-butyllithium (9.5 ml,
20.1 mmol, 2.13 M pentane solution)
Stirred at 78 ° C. for 1 hour. At -100 ° C, a solution of the compound obtained in the above (1) (3.91 g, 10.1 mmol) in ether (10 ml) was added, and the temperature was raised to -50 ° C over 3 hours. Saturated aqueous ammonium chloride solution (100
ml) and extracted with hexane (50 ml × 2).
The obtained organic layer was dried over magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure, and the crude product obtained was purified by silica gel column chromatography to obtain compound (3)
RS, 4S * , 5R * )-3-Hydroxy-3- (4-methoxy-1-butyl) -4- [2- (3-methoxycarbonyl-1-propyl) phenyl] -5- (tert-
Butyldimethylsiloxy) -1-cyclopentene (1.
68g) was obtained with a yield of 35%.
【0051】1H−NMR(CDCl3,200MHz)
δppm;−0.24(s,3H),−0.14(s,
3H),0.78(s,9H),1.37−2.14
(m,9H),2.26−2.90(m,2H),2.
39(t,J=7.3Hz,2H),3.22−3.5
0(m,3H),3.30(s,3H),3.68
(s,3H),5.04−5.12(m,1H),5.
98(dd,J=5.7,1.1Hz,1H),6.0
5(dd,J=5.7,1.5Hz,1H),7.10
−7.46(m,4H) IR(neat):3467,3058,3019,2
952,2930,2858,1741,1492,1
463,1437,1363,1253,1118,1
074,995,940,881,837,779,7
54,670cm-1 MS(SIMS)(+KI)m/z:515(M
K+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; -0.24 (s, 3H), -0.14 (s,
3H), 0.78 (s, 9H), 1.37-2.14
(M, 9H), 2.26-2.90 (m, 2H), 2.
39 (t, J = 7.3 Hz, 2H), 3.22-3.5
0 (m, 3H), 3.30 (s, 3H), 3.68
(S, 3H), 5.04-5.12 (m, 1H), 5.
98 (dd, J = 5.7, 1.1 Hz, 1H), 6.0
5 (dd, J = 5.7, 1.5 Hz, 1H), 7.10
-7.46 (m, 4H) IR (neat): 3467, 3058, 3019, 2
952, 2930, 2858, 1741, 1492, 1
463, 1437, 1363, 1253, 1118, 1
074,995,940,881,837,779,7
54,670 cm -1 MS (SIMS) (+ KI) m / z: 515 (M
K + ).
【0052】(3)上記(2)で得た化合物(1.67
g、3.5mmol)のTHF(51ml)溶液に、室
温でテトラブチルアンモニウムフルオリド(1.37
g,5.3mmol)を加え、室温で一昼夜攪拌した
後、40℃で2時間攪拌した。反応液に飽和塩化アンモ
ニウム水溶液(50ml)を加え、酢酸エチル(30m
l×2)で抽出した。得られた有機層を硫酸マグネシウ
ムで乾燥した後、濾過した。濾液を減圧下濃縮して得ら
れた粗精製物をシリカゲルカラムクロマトグラフィーで
精製して化合物 (3RS,4S*,5R*)−3−(4
−メトキシ−1−ブチル)−4−[2−(3−メトキシ
−1−プロピル)フェニル]−3,5−ジヒドロキシ−
1−シクロペンテン(850mg)を収率67%で得
た。(3) The compound obtained in the above (2) (1.67)
g, 3.5 mmol) in THF (51 ml) at room temperature in tetrabutylammonium fluoride (1.37).
g, 5.3 mmol), and the mixture was stirred at room temperature for 24 hours, and then stirred at 40 ° C. for 2 hours. A saturated aqueous ammonium chloride solution (50 ml) was added to the reaction solution, and ethyl acetate (30 m
1 × 2). The obtained organic layer was dried over magnesium sulfate and then filtered. The crude product obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography to obtain compound (3RS, 4S * , 5R * )-3- (4
-Methoxy-1-butyl) -4- [2- (3-methoxy-1-propyl) phenyl] -3,5-dihydroxy-
1-Cyclopentene (850 mg) was obtained with a yield of 67%.
【0053】1H−NMR(CDCl3,200MHz)
δppm;1.17−2.11(m,10H),2.3
2−2.96(m,2H),2.40(t,J=6.7
Hz,2H),3.30(s,3H),3.36(t,
J=6.7Hz,2H),3.43(d,J=5.3H
z,1H),3.57(s,3H),5.06−5.1
4(m,1H),6.02(dd,J=5.7,1.8
Hz,1H),6.17(dd,J=5.7,1.3H
z,1H),7.14−7.44(m,4H) IR(neat):3427,3056,2945,2
871,1733,1491,1439,1368,1
202,1149,1114,1058,916,87
9,832,756,644cm-1 MS(SIMS)(+KI)m/z:401(M
K+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.17-2.11 (m, 10H), 2.3
2-2.96 (m, 2H), 2.40 (t, J = 6.7)
Hz, 2H), 3.30 (s, 3H), 3.36 (t,
J = 6.7 Hz, 2H), 3.43 (d, J = 5.3H)
z, 1H), 3.57 (s, 3H), 5.06-5.1.
4 (m, 1H), 6.02 (dd, J = 5.7, 1.8
Hz, 1H), 6.17 (dd, J = 5.7, 1.3H)
z, 1H), 7.14-7.44 (m, 4H) IR (neat): 3427, 3056, 2945, 2
871,1733,1491,1439,1368,1
202, 1149, 1114, 1058, 916, 87
9,832,756,644 cm -1 MS (SIMS) (+ KI) m / z: 401 (M
K + ).
【0054】(4)上記(3)で得た化合物(840m
g,2.32mmol)の塩化メチレン(46ml)溶
液に、室温で二酸化マンガン(8.40g,96.6m
mol)を加え、室温で2日間激しく攪拌した。反応混
合物を濾過後、濾液を減圧下濃縮して得られた粗精製物
をシリカゲルカラムクロマトグラフィーで精製して標記
化合物(509mg)を収率61%で得た。(4) The compound obtained in the above (3) (840 m
g, 2.32 mmol) in methylene chloride (46 ml) at room temperature in manganese dioxide (8.40 g, 96.6 m).
mol) was added and stirred vigorously at room temperature for 2 days. After filtering the reaction mixture, the filtrate was concentrated under reduced pressure, and the crude product obtained was purified by silica gel column chromatography to give the title compound (509 mg) at a yield of 61%.
【0055】1H−NMR(CDCl3,300MHz)
δppm;1.46−2.08(m,9H),2.41
(t,J=6.9Hz,2H),2.57−2.84
(m,2H),3.32(s,3H),3.40(t,
J=6.2Hz,2H),3.65(s,3H),3.
99(s,1H),6.40(d,J=5.7Hz,1
H),6.82−6.90(m,1H),7.13−
7.30(m,3H),7.63(d,J=5.7H
z,1H) IR(neat):3436,2945,2869,1
734,1713,1600,1493,1438,1
365,1337,1197,1147,1116,8
79,796,755,701cm-1 MS(SIMS)m/z:399(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.46 to 2.08 (m, 9H), 2.41
(T, J = 6.9 Hz, 2H), 2.57-2.84
(M, 2H), 3.32 (s, 3H), 3.40 (t,
J = 6.2 Hz, 2H), 3.65 (s, 3H), 3.
99 (s, 1H), 6.40 (d, J = 5.7 Hz, 1
H), 6.82-6.90 (m, 1H), 7.13-
7.30 (m, 3H), 7.63 (d, J = 5.7H
z, 1H) IR (neat): 3436, 2945, 2869, 1
732, 1713, 1600, 1493, 1438, 1
365, 1337, 1197, 1147, 1116, 8
79, 796, 755, 701 cm -1 MS (SIMS) m / z: 399 (MK + ).
【0056】実施例2(4R*,5R*)−4−ヒドロキシ−4−(4−メトキ
シ−1−ブチル)−5−[2−(4−メトキシ−1−ブ
チル)フェニル]−2−シクロペンテン−1−オン (1)実施例1(1)において、メチル 3−ブテノエ
ートの代わりに1−メトキシ−3−ブテンを用い、実施
例1(1)と実質的に同様にして(4R*,5S*)−4
−(tert−ブチルジメチルシロキシ)−5−[2−
(4−メトキシ−1−ブチル)フェニル]−2−シクロ
ペンテン−1−オンを得た。Example 2 (4R * , 5R * )-4-hydroxy-4- (4-methoxy)
Ci-1-butyl) -5- [2- (4-methoxy-1-bu
Tyl) phenyl] -2-cyclopenten- 1-one (1) Substantially the same as in Example 1 (1) except that 1-methoxy-3-butene was used in place of methyl 3-butenoate in Example 1 (1). Similarly, (4R * , 5S * )-4
-(Tert-butyldimethylsiloxy) -5- [2-
(4-Methoxy-1-butyl) phenyl] -2-cyclopenten-1-one was obtained.
【0057】1H−NMR(CDCl3,300MHz)
δppm;−0.13(s,3H),−0.05(s,
3H),0.86(s,9H),1.32−1.94
(m,4H),2.47−2.77(m,2H),3.
32(s,3H),3.38(t,J=6.2Hz,2
H),3.72(d,J=2.7Hz,1H),4.8
8−4.94(m,1H),6.32(dd,J=5.
8,1.2Hz,1H),6.76−6.88(m,1
H),7.10−7.24(m,3H),7.52(d
d,J=5.8,2.0Hz,1H) IR(neat):3063,3018,2929,2
859,1723,1595,1494,1471,1
452,1412,1389,1362,1341,1
331,1302,1254,1197,1168,1
120,1076,1007,985,940,88
8,842,815,780,752,675,63
8,559,518 cm-1 MS(CI)m/z: 375(MH+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; -0.13 (s, 3H), -0.05 (s,
3H), 0.86 (s, 9H), 1.32-1.94.
(M, 4H), 2.47-2.77 (m, 2H), 3.
32 (s, 3H), 3.38 (t, J = 6.2 Hz, 2
H), 3.72 (d, J = 2.7 Hz, 1H), 4.8.
8-4.94 (m, 1H), 6.32 (dd, J = 5.
8, 1.2 Hz, 1 H), 6.76-6.88 (m, 1
H), 7.10-7.24 (m, 3H), 7.52 (d
d, J = 5.8, 2.0 Hz, 1H) IR (neat): 3063, 3018, 2929, 2
859, 1723, 1595, 1494, 1471, 1
452, 1412, 1389, 1362, 1341, 1
331, 1302, 1254, 1197, 1168, 1
120, 1076, 1007, 985, 940, 88
8,842,815,780,752,675,63
8,559,518 cm < -1 > MS (CI) m / z: 375 (MH <+> ).
【0058】(2)上記(1)で得た化合物を用い、実
施例1(2)と実質的に同様にして(3S*,4S*,5
R*)−3−ヒドロキシ−3−(4−メトキシ−1−ブ
チル)−4−[2−(4−メトキシ−1−ブチル)フェ
ニル]−5−(tert−ブチルジメチルシロキシ)−
1−シクロペンテンおよび(3R*,4S*,5R*)−
3−ヒドロキシ−3−(4−メトキシ−1−ブチル)−
4−[2−(4−メトキシ−1−ブチル)フェニル]−
5−(tert−ブチルジメチルシロキシ)−1−シク
ロペンテンを得た。(2) Using the compound obtained in the above (1), (3S * , 4S * , 5
R * )-3-Hydroxy-3- (4-methoxy-1-butyl) -4- [2- (4-methoxy-1-butyl) phenyl] -5- (tert-butyldimethylsiloxy)-
1-cyclopentene and (3R * , 4S * , 5R * )-
3-hydroxy-3- (4-methoxy-1-butyl)-
4- [2- (4-methoxy-1-butyl) phenyl]-
5- (tert-Butyldimethylsiloxy) -1-cyclopentene was obtained.
【0059】(3S*,4S*,5R*)−3−ヒドロキ
シ−3−(4−メトキシ−1−ブチル)−4−[2−
(4−メトキシ−1−ブチル)フェニル]−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン 1 H−NMR(CDCl3,200MHz)δppm;−
0.23(s,3H),−0.08(s,3H),0.
79(s,9H),1.07−2.07(m,11
H),2.45−2.68(m,1H),2.86−
3.09(m,1H),3.17−3.51(m,4
H),3.26(s,3H),3.32(s,3H),
3.58(d,J=5.5Hz,1H),4.83−
4.91(m,1H),5.93(dd,J=5.7,
1.8Hz,1H),6.05(dd,J=5.7,
0.9Hz,1H),7.08−7.23(m,4H) IR(neat):3436,3058,3021,2
931,2858,1744,1711,1489,1
471,1462,1387,1363,1254,1
113,993,940,882,864,837,7
77,754,672 cm-1 MS(FAB)(+KI)m/z:501(MK+)。 (3S * , 4S * , 5R * )-3-hydroxy
C-3- (4-methoxy-1-butyl) -4- [2-
(4-methoxy-1-butyl) phenyl] -5- (te
rt-butyldimethylsiloxy) -1-cyclopentene 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.23 (s, 3H), -0.08 (s, 3H), 0.
79 (s, 9H), 1.07 to 2.07 (m, 11
H), 2.45-2.68 (m, 1H), 2.86-
3.09 (m, 1H), 3.17-3.51 (m, 4
H), 3.26 (s, 3H), 3.32 (s, 3H),
3.58 (d, J = 5.5 Hz, 1H), 4.83 −
4.91 (m, 1H), 5.93 (dd, J = 5.7,
1.8 Hz, 1 H), 6.05 (dd, J = 5.7,
0.9Hz, 1H), 7.08-7.23 (m, 4H) IR (neat): 3436, 3058, 3021,
931, 2858, 1744, 1711, 1489, 1
471, 1462, 1387, 1363, 1254, 1
113,993,940,882,864,837,7
77, 754, 672 cm -1 MS (FAB) (+ KI) m / z: 501 (MK + ).
【0060】(3R*,4S*,5R*)−3−ヒドロキ
シ−3−(4−メトキシ−1−ブチル)−4−[2−
(4−メトキシ−1−ブチル)フェニル]−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン 1 H−NMR(CDCl3,200MHz)δppm;−
0.23(s,3H),−0.15(s,3H),0.
80(s,9H),1.13−1.87(m,11
H),2.42−2.87(m,2H),3.18−
3.50(m,5H),3.30(s,3H),3.3
3(s,3H),5.04−5.12(m,1H),
5.98(dd,J=5.7,1.1Hz,1H),
6.05(dd,J=5.7,1.6Hz,1H),
7.11−7.23(m,3H),7.31−7.43
(m,1H) IR(neat):3437,3058,2931,2
858,1742,1492,1472,1463,1
386,1362,1253,1120,1075,9
95,940,882,837,777,754,66
9 cm-1 MS(FAB)(+KI)m/z:501(MK+)。 (3R * , 4S * , 5R * )-3-hydroxy
C-3- (4-methoxy-1-butyl) -4- [2-
(4-methoxy-1-butyl) phenyl] -5- (te
rt-butyldimethylsiloxy) -1-cyclopentene 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.23 (s, 3H), -0.15 (s, 3H), 0.
80 (s, 9H), 1.13-1.87 (m, 11
H), 2.42-2.87 (m, 2H), 3.18-
3.50 (m, 5H), 3.30 (s, 3H), 3.3
3 (s, 3H), 5.04-5.12 (m, 1H),
5.98 (dd, J = 5.7, 1.1 Hz, 1H),
6.05 (dd, J = 5.7, 1.6 Hz, 1H),
7.11-7.23 (m, 3H), 7.31-7.43
(M, 1H) IR (neat): 3437, 3058, 2931, 2
858,1742,1492,1472,1463,1
386, 1362, 1253, 1120, 1075, 9
95,940,882,837,777,754,66
9 cm -1 MS (FAB) (+ KI) m / z: 501 (MK + ).
【0061】(3)上記(2)で得た(3R*,4S*,
5R*)−3−ヒドロキシ−3−(4−メトキシ−1−
ブチル)−4−[2−(4−メトキシ−1−ブチル)フ
ェニル]−5−(tert−ブチルジメチルシロキシ)
−1−シクロペンテンを用い、実施例1(3)と実質的
に同様にして(3R*,4S*,5R*)−3−(4−メ
トキシ−1−ブチル)−4−[2−(4−メトキシ−1
−ブチル)フェニル]−3,5−ジヒドロキシ−1−シ
クロペンテンを得た。(3) (3R * , 4S * ,
5R * )-3-Hydroxy-3- (4-methoxy-1-
Butyl) -4- [2- (4-methoxy-1-butyl) phenyl] -5- (tert-butyldimethylsiloxy)
Using (-1-cyclopentene) and substantially the same as in Example 1 (3), (3R * , 4S * , 5R * )-3- (4-methoxy-1-butyl) -4- [2- (4 -Methoxy-1
-Butyl) phenyl] -3,5-dihydroxy-1-cyclopentene.
【0062】1H−NMR(CDCl3,200MHz)
δppm;1.33−1.92(m,12H),2.4
6−2.65(m,1H),2.74−2.96(m,
1H),3.22−3.50(m,5H),3.36
(s,6H),5.03−5.12(m,1H),6.
03(dd,J=5.7,1.3Hz,1H),6.1
4(dd,J=5.7,1.8Hz,1H),7.16
−7.28(m,3H),7.32−7.42(m,1
H) IR(neat):3413,3056,2936,2
868,1490,1451,1387,1117,1
060,755 cm-1 MS(FAB)(+KI)m/z:387(MK+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.33-1.92 (m, 12H), 2.4
6-2.65 (m, 1H), 2.74-2.96 (m, 1H)
1H), 3.22-3.50 (m, 5H), 3.36.
(S, 6H), 5.03-5.12 (m, 1H), 6.
03 (dd, J = 5.7, 1.3 Hz, 1H), 6.1
4 (dd, J = 5.7, 1.8 Hz, 1H), 7.16
−7.28 (m, 3H), 7.32 to 7.42 (m, 1
H) IR (neat): 3413, 3056, 2936, 2
868, 1490, 1451, 1387, 1117, 1
060, 755 cm- 1 MS (FAB) (+ KI) m / z: 387 (MK + ).
【0063】(4)上記(3)で得た化合物を用い、実
施例1(4)と実質的に同様にして標記化合物を得た。(4) Using the compound obtained in the above (3), the title compound was obtained in substantially the same manner as in Example 1 (4).
【0064】1H−NMR(CDCl3,300MHz)
δppm;1.44−2.02(m,10H),1.7
4(s,1H),2.55−2.83(m,2H),
3.32(s,6H),3.39(t,J=6.1H
z,2H),3.40(t,J=5.8Hz,2H),
3.93(s,1H),6.40(d,J=5.7H
z,1H),6.84(d,J=7.1Hz,1H),
7.12−7.32(m,3H),7.62(d,J=
5.7Hz,1H) IR(neat):3408,3061,2936,2
867,1714,1600,1493,1461,1
387,1336,1192,1118,921,79
4,754,700 cm-1 MS(FAB)m/z:347(MH+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.44-2.02 (m, 10H), 1.7
4 (s, 1H), 2.55-2.83 (m, 2H),
3.32 (s, 6H), 3.39 (t, J = 6.1H)
z, 2H), 3.40 (t, J = 5.8 Hz, 2H),
3.93 (s, 1H), 6.40 (d, J = 5.7H)
z, 1H), 6.84 (d, J = 7.1 Hz, 1H),
7.12-7.32 (m, 3H), 7.62 (d, J =
5.7 Hz, 1 H) IR (neat): 3408, 3061, 2936, 2
867, 1714, 1600, 1493, 1461, 1
387, 1336, 1192, 1118, 921, 79
4,754,700 cm -1 MS (FAB) m / z: 347 (MH <+> ).
【0065】実施例3(4R*,5R*)−4−ヒドロキシ−4−(4−メトキ
シ−1−ブチル)−5−[2−(4−ヒドロキシ−1−
ブチル)フェニル]−2−シクロペンテン−1−オン
(化合物2) (1)実施例1(1)において、メチル 3−ブテノエ
ートの代わりに1−(tert−ブチルジメチルシロキ
シ)−3−ブテンを用い、実施例1(1)と実質的に同
様にして(4R*,5S*)−4−(tert−ブチルジ
メチルシロキシ)−5−[2−(4−tert−ブチル
ジメチルシロキシ−1−ブチル)フェニル]−2−シク
ロペンテン−1−オンを得た。Embodiment 3(4R * , 5R * )-4-hydroxy-4- (4-methoxy)
Ci-1-butyl) -5- [2- (4-hydroxy-1-
Butyl) phenyl] -2-cyclopenten-1-one
(Compound 2) (1) In Example 1 (1), methyl 3-butenoe
1- (tert-butyldimethylsiloxy)
C) Using 3-butene, substantially the same as in Example 1 (1).
(4R*, 5S*) -4- (tert-Butyldi)
Methylsiloxy) -5- [2- (4-tert-butyl
Dimethylsiloxy-1-butyl) phenyl] -2-cycl
Lopenten-1-one was obtained.
【0066】1H−NMR(CDCl3,200MHz)
δppm;−0.13(s,3H),−0.05(s,
3H),0.04(s,6H),0.86(s,9
H),0.89(s,9H),1.46−1.75
(m,4H),2.35−2.83(m,2H),3.
62(t,J=6.0Hz,2H),3.72(d,J
=2.6Hz,1H),4.86−4.93(m,1
H),6.32(dd,J=5.8,1.2Hz,1
H),6.77−6.87(m,1H),7.07−
7.29(m,3H),7.52(dd,J=5.8,
2.1Hz,1H) IR(neat):2954,2930,2886,2
858,1723,1494,1472,1388,1
362,1331,1255,1199,1113,1
077,1007,984,940,888,839,
778,751,666cm-1 MS(CI)m/z:475(MH+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; -0.13 (s, 3H), -0.05 (s,
3H), 0.04 (s, 6H), 0.86 (s, 9
H), 0.89 (s, 9H), 1.46-1.75.
(M, 4H), 2.35-2.83 (m, 2H), 3.
62 (t, J = 6.0 Hz, 2H), 3.72 (d, J
= 2.6 Hz, 1H), 4.86-4.93 (m, 1
H), 6.32 (dd, J = 5.8, 1.2 Hz, 1
H), 6.77-6.87 (m, 1H), 7.07-
7.29 (m, 3H), 7.52 (dd, J = 5.8,
2.1 Hz, 1 H) IR (neat): 2954, 2930, 2886, 2
858, 1723, 1494, 1472, 1388, 1
362,1331,1255,1199,1113,1
077,1007,984,940,888,839,
778, 751, 666 cm -1 MS (CI) m / z: 475 (MH <+> ).
【0067】(2)上記(1)で得た化合物を用い、実
施例1(2)と実質的に同様にして(3S*,4S*,5
R*)−3−ヒドロキシ−3−(4−メトキシ−1−ブ
チル)−4−[2−(4−tert−ブチルジメチルシ
ロキシ−1−ブチル)フェニル]−5−(tert−ブ
チルジメチルシロキシ)−1−シクロペンテンおよび
(3R*,4S*,5R*)−3−ヒドロキシ−3−(4
−メトキシ−1−ブチル)−4−[2−(4−tert
−ブチルジメチルシロキシ−1−ブチル)フェニル]−
5−(tert−ブチルジメチルシロキシ)−1−シク
ロペンテンを得た。(2) Using the compound obtained in the above (1), (3S * , 4S * , 5
R * )-3-Hydroxy-3- (4-methoxy-1-butyl) -4- [2- (4-tert-butyldimethylsiloxy-1-butyl) phenyl] -5- (tert-butyldimethylsiloxy) -1-cyclopentene and (3R * , 4S * , 5R * )-3-hydroxy-3- (4
-Methoxy-1-butyl) -4- [2- (4-tert
-Butyldimethylsiloxy-1-butyl) phenyl]-
5- (tert-Butyldimethylsiloxy) -1-cyclopentene was obtained.
【0068】(3S*,4S*,5R*)−3−ヒドロキ
シ−3−(4−メトキシ−1−ブチル)−4−[2−
(4−tert−ブチルジメチルシロキシ−1−ブチ
ル)フェニル]−5−(tert−ブチルジメチルシロ
キシ)−1−シクロペンテン 1 H−NMR(CDCl3,200MHz)δppm;−
0.22(s,3H),−0.07(s,3H),0.
05(s,6H), 0.79(s,9H),0.89
(s,9H),1.02−1.96(m,11H),
2.46−2.66(m,1H),2.86−3.06
(m,1H),3.12−3.44(m,2H),3.
25(s,3H),3.48−3.74(m,2H),
3.57(d,J=5.3Hz,1H),4.78−
4.90(m,1H),5.95(dd,J=5.8,
1.6Hz,1H),6.05(dd,J=5.8,
0.8Hz,1H),7.02−7.30(m,4H) IR(neat):3431,3059,3022,2
930,2858,1603,1472,1463,1
412,1388,1362,1342,1301,1
255,1103,1006,994,940,83
7,776,752,672 cm-1 MS(FAB)(+KI)m/z:601(MK+)。 (3S * , 4S * , 5R * )-3-hydroxy
C-3- (4-methoxy-1-butyl) -4- [2-
(4-tert-butyldimethylsiloxy-1-butyi)
Phenyl ) -5- (tert-butyldimethylsilo )
Xy) -1-cyclopentene 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.22 (s, 3H), -0.07 (s, 3H), 0.
05 (s, 6H), 0.79 (s, 9H), 0.89
(S, 9H), 1.02-1.96 (m, 11H),
2.46-2.66 (m, 1H), 2.86-3.06
(M, 1H), 3.12-3.44 (m, 2H), 3.
25 (s, 3H), 3.48-3.74 (m, 2H),
3.57 (d, J = 5.3 Hz, 1H), 4.78-
4.90 (m, 1H), 5.95 (dd, J = 5.8,
1.6 Hz, 1 H), 6.05 (dd, J = 5.8,
0.8Hz, 1H), 7.02-7.30 (m, 4H) IR (neat): 3431, 3059, 3022, 2
930,2858,1603,1472,1463,1
412, 1388, 1362, 1342, 1301, 1
255,1103,1006,994,940,83
7,776,752,672 cm -1 MS (FAB) (+ KI) m / z: 601 (MK + ).
【0069】(3R*,4S*,5R*)−3−ヒドロキ
シ−3−(4−メトキシ−1−ブチル)−4−[2−
(4−tert−ブチルジメチルシロキシ−1−ブチ
ル)フェニル]−5−(tert−ブチルジメチルシロ
キシ)−1−シクロペンテン 1 H−NMR(CDCl3,200MHz)δppm;−
0.24(s,3H),−0.15(s,3H),0.
05(s,6H),0.79(s,9H),0.90
(s,9H),1.14−1.88(m,11H),
2.43−2.86(m,2H),3.18−3.48
(m,3H),3.30(s,3H),3.50−3.
74(m,2H),5.00−5.12(m,1H),
5.97(dd,J=5.7,1.1Hz,1H),
6.05(dd,J=5.7,1.5Hz,1H),
7.08−7.24(m,3H),7.32−7.42
(m,1H) IR(neat):3430,3059,3023,2
930,2889,2858,1602,1490,1
472,1463,1387,1362,1255,1
186,1103,1076,995,940,88
3,837,776,753,666 cm-1 MS(FAB)(+KI)m/z:601(MK+)。 (3R * , 4S * , 5R * )-3-hydroxy
C-3- (4-methoxy-1-butyl) -4- [2-
(4-tert-butyldimethylsiloxy-1-butyi)
Phenyl ) -5- (tert-butyldimethylsilo )
Xy) -1-cyclopentene 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
0.24 (s, 3H), -0.15 (s, 3H), 0.
05 (s, 6H), 0.79 (s, 9H), 0.90
(S, 9H), 1.14-1.88 (m, 11H),
2.43-2.86 (m, 2H), 3.18-3.48
(M, 3H), 3.30 (s, 3H), 3.50-3.
74 (m, 2H), 5.00-5.12 (m, 1H),
5.97 (dd, J = 5.7, 1.1 Hz, 1H),
6.05 (dd, J = 5.7, 1.5 Hz, 1H),
7.08-7.24 (m, 3H), 7.32-7.42
(M, 1H) IR (neat): 3430, 3059, 3023, 2
930, 2889, 2858, 1602, 1490, 1
472,1463,1387,1362,1255,1
186,1103,1076,995,940,88
3,837,776,753,666 cm -1 MS (FAB) (+ KI) m / z: 601 (MK + ).
【0070】(3)上記(2)で得た(3R*,4S*,
5R*)−3−ヒドロキシ−3−(4−メトキシ−1−
ブチル)−4−[2−(4−tert−ブチルジメチル
シロキシ−1−ブチル)フェニル]−5−(tert−
ブチルジメチルシロキシ)−1−シクロペンテンを用
い、実施例1(3)と実質的に同様にして(3R*,4
S*,5R*)−3,5−ジヒドロキシ−3−(4−メト
キシ−1−ブチル)−4−[2−(4−ヒドロキシ−1
−ブチル)フェニル]−1−シクロペンテンを得た。(3) (3R * , 4S * ,
5R * )-3-Hydroxy-3- (4-methoxy-1-
Butyl) -4- [2- (4-tert-butyldimethylsiloxy-1-butyl) phenyl] -5- (tert-
Using (butyldimethylsiloxy) -1-cyclopentene (3R * , 4) in substantially the same manner as in Example 1 (3).
S * , 5R * )-3,5-dihydroxy-3- (4-methoxy-1-butyl) -4- [2- (4-hydroxy-1
-Butyl) phenyl] -1-cyclopentene was obtained.
【0071】1H−NMR(CDCl3,200MHz)
δppm;1.15−2.05(m,13H),2.4
5−2.64(m,1H),2.73−2.94(m,
1H),3.31(s,3H),3.33−3.43
(m,3H),3.54−3.74(m,2H),5.
01−5.10(m,1H),6.00(dd,J=
5.7,1.2Hz,1H),6.11(dd,J=
5.7,1.8Hz,1H),7.16−7.40
(m,4H) IR(neat):3401,3057,3020,2
932,2872,1729,1633,1601,1
581,1490,1456,1385,1276,1
188,1119,1071,832,753,70
5,644 cm-1。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; 1.15 to 2.05 (m, 13H), 2.4
5-2.64 (m, 1H), 2.73-2.94 (m, 1H)
1H), 3.31 (s, 3H), 3.33-3.43.
(M, 3H), 3.54-3.74 (m, 2H), 5.
01-5.10 (m, 1H), 6.00 (dd, J =
5.7, 1.2 Hz, 1H), 6.11 (dd, J =
5.7, 1.8 Hz, 1H), 7.16-7.40
(M, 4H) IR (neat): 3401, 3057, 3020, 2
932,2872,1729,1633,1601,1
581, 1490, 1456, 1385, 1276, 1
188, 1119, 1071, 832, 753, 70
5,644 cm -1 .
【0072】(4)上記(3)で得た化合物を用い、実
施例1(4)と実質的に同様にして標記化合物を得た。(4) Using the compound obtained in the above (3), the title compound was obtained in substantially the same manner as in Example 1 (4).
【0073】1H−NMR(CDCl3,300MHz)
δppm;1.18−2.06(m,12H),2.5
4−2.87(m,2H),3.33(s,3H),
3.35−3.47(m,2H),3.61−3.72
(m,2H)3.98(s,3H),6.40(d,J
=5.8Hz,1H),6.85(d,J=7.1H
z,1H),7.13−7.33(m,3H),7.6
1(d,J=5.8Hz,1H) IR(neat):3399,3059,3024,2
937,2867,1713,1600,1493,1
455,1385,1337,1192,1114,1
070,918,795,754,701,592 c
m-1 MS(FAB)(+KI)m/z:371(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.18 to 2.06 (m, 12H), 2.5
4-2.87 (m, 2H), 3.33 (s, 3H),
3.35-3.47 (m, 2H), 3.61-3.72
(M, 2H) 3.98 (s, 3H), 6.40 (d, J
= 5.8 Hz, 1H), 6.85 (d, J = 7.1H)
z, 1H), 7.13-7.33 (m, 3H), 7.6.
1 (d, J = 5.8 Hz, 1H) IR (neat): 3399, 3059, 3024, 2
937, 2867, 1713, 1600, 1493, 1
455, 1385, 1337, 1192, 1114, 1
070,918,795,754,701,592c
m -1 MS (FAB) (+ KI) m / z: 371 (MK + ).
【0074】実施例4(4R*,5R*)−4−ヒドロキシ−4−(4−メトキ
シ−1−ブチル)−5−フェニル−2−シクロペンテン
−1−オン (1)実施例1(2)において、(4R*,5S*)−4
−(tert−ブチルジメチルシロキシ)−5−[2−
(3−メトキシカルボニル−1−プロピル)フェニル]
−2−シクロペンテン−1−オンの代わりに参考例2で
得た(4R*,5S*)−5−フェニル−4−(tert
ーブチルジメチルシロキシ)−2−シクロペンテン−1
−オンを用い、実施例1(2)と実質的に同様にして
(3R*,4S*,5R*)−3−ヒドロキシ−3−(4
−メトキシ−1−ブチル)−4−フェニル−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン
を得た。Example 4 (4R * , 5R * )-4-hydroxy-4- (4-methoxy)
1-butyl) -5-phenyl-2-cyclopentene
-1-one (1) In Example 1 (2), (4R * , 5S * )-4
-(Tert-butyldimethylsiloxy) -5- [2-
(3-methoxycarbonyl-1-propyl) phenyl]
(4R * , 5S * )-5-phenyl-4- (tert) obtained in Reference Example 2 instead of -2-cyclopenten-1-one
-Butyldimethylsiloxy) -2-cyclopentene-1
(3R * , 4S * , 5R * )-3-hydroxy-3- (4
-Methoxy-1-butyl) -4-phenyl-5- (te
(rt-butyldimethylsiloxy) -1-cyclopentene was obtained.
【0075】1H−NMR(CDCl3,300MHz)
δppm;−0.24(s,3H),−0.14(s,
3H),0.77(s,9H),1.13−1.66
(m,7H),2.99(d,J=5.9Hz,1
H),3.31(s,3H),3.36(t,J=6.
2Hz,1H),5.11−5.18(m,1H),
5.94(dd,J=5.9,1.4Hz,1H),
6.03(dd,J=5.9,1.6Hz,1H),
7.20−7.40(m,5H) IR(neat):3436,3060,3030,2
929,2858,1945,1746,1706,1
603,1496,1472,1462,1388,1
362,1347,1252,1188,1119,9
95,940,883,865,837,775,74
4,702,670,523 cm-1 MS(FAB)(+KI)m/z:415(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; -0.24 (s, 3H), -0.14 (s,
3H), 0.77 (s, 9H), 1.13-1.66
(M, 7H), 2.99 (d, J = 5.9 Hz, 1
H), 3.31 (s, 3H), 3.36 (t, J = 6.
2Hz, 1H), 5.11-5.18 (m, 1H),
5.94 (dd, J = 5.9, 1.4 Hz, 1H),
6.03 (dd, J = 5.9, 1.6 Hz, 1H),
7.20-7.40 (m, 5H) IR (neat): 3436, 3060, 3030, 2
929, 2858, 1945, 1746, 1706, 1
603, 1496, 1472, 1462, 1388, 1
362, 1347, 1252, 1188, 1119, 9
95,940,883,865,837,775,74
4,702,670,523 cm- 1 MS (FAB) (+ KI) m / z: 415 (MK + ).
【0076】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして(3R*,4S*,5
R*)−3,5−ジヒドロキシ−3−(4−メトキシ−
1−ブチル)−4−フェニル−1−シクロペンテンを得
た。(2) Using the compound obtained in the above (1), (3R * , 4S * , 5) was prepared in substantially the same manner as in Example 1 (3).
R * )-3,5-dihydroxy-3- (4-methoxy-
1-butyl) -4-phenyl-1-cyclopentene was obtained.
【0077】1H−NMR(CDCl3,300MHz)
δppm;1.09−1.69(m,7H),1.88
−1.97(br,1H),3.01(d,J=6.1
Hz,1H),3.30(s,3H),3.37(t,
J=6.1Hz,2H),5.19−5.26(m,1
H),5.98(dd,J=5.8,1.5Hz,1
H),6.12(dd,J=5.8,1.7Hz,1
H),7.23−7.41(m,5H) IR(neat):3392,3058,3029,2
937,2867,1602,1496,1454,1
391,1334,1188,1111,1062,9
70,917,831,775,743,704,65
0,529 cm-1 MS(FAB)(+KI)m/z:301(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.09-1.69 (m, 7H), 1.88
-1.97 (br, 1H), 3.01 (d, J = 6.1)
Hz, 1H), 3.30 (s, 3H), 3.37 (t,
J = 6.1 Hz, 2H), 5.19-5.26 (m, 1
H), 5.98 (dd, J = 5.8, 1.5 Hz, 1
H), 6.12 (dd, J = 5.8, 1.7 Hz, 1
H), 7.23-7.41 (m, 5H) IR (neat): 3392, 3058, 3029, 2
937, 2867, 1602, 1496, 1454, 1
391, 1334, 1188, 1111, 1062, 9
70,917,831,775,743,704,65
0.529 cm < -1 > MS (FAB) (+ KI) m / z: 301 (MK <+> ).
【0078】(3)上記(2)で得た化合物を用い、実
施例1(4)と実質的に同様にして標記化合物を得た。(3) Using the compound obtained in the above (2), the title compound was obtained in substantially the same manner as in Example 1 (4).
【0079】1H−NMR(CDCl3,300MHz)
δppm;1.48−1.70(m,5H),1.76
−1.94(m,1H),3.32(s,3H),3.
40(t,J=6.0Hz,2H),3.65(s,1
H),6.37(d,J=5.8Hz,2H),7.0
6−7.12(m,2H),7.28−7.41(m,
5H),7.59(d,J=5.8Hz,1H) IR(neat):3416,3030,2936,2
867,1713,1601,1498,1454,1
390,1338,1191,1115,918,79
8,746,703 cm-1 MS(FAB)(+KI)m/z:299(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.48-1.70 (m, 5H), 1.76
-1.94 (m, 1H), 3.32 (s, 3H), 3.
40 (t, J = 6.0 Hz, 2H), 3.65 (s, 1
H), 6.37 (d, J = 5.8 Hz, 2H), 7.0.
6-7.12 (m, 2H), 7.28-7.41 (m,
5H), 7.59 (d, J = 5.8 Hz, 1H) IR (neat): 3416, 3030, 2936, 2
867, 1713, 1601, 1498, 1454, 1
390, 1338, 1191, 1115, 918, 79
8,746,703 cm -1 MS (FAB) (+ KI) m / z: 299 (MK + ).
【0080】実施例5(4R*,5R*)−4−ヒドロキシ−4−(4−フェノ
キシ−1−ブチル)−5−[2−(3−メトキシカルボ
ニル−1−プロピル)フェニル]−2−シクロペンテン
−1−オン (1)実施例1(2)において、4−ブロモ−1−メト
キシブタンの代わりに4−ブロモ−1−フェノキシブタ
ンを用い、実施例1(2)と実質的に同様にして(3R
*,4S*,5R*)−3−ヒドロキシ−3−(4−フェ
ノキシ−1−ブチル)−4−[2−(3−メトキシカル
ボニル−1−プロピル)フェニル]−5−(tert−
ブチルジメチルシロキシ)−1−シクロペンテンを得
た。Example 5 (4R * , 5R * )-4-hydroxy-4- (4-pheno)
Xy-1-butyl) -5- [2- (3-methoxycarbo
Nil-1-propyl) phenyl] -2-cyclopentene
-1-one (1) In the same manner as in Example 1 (2), except that 4-bromo-1-phenoxybutane was used in place of 4-bromo-1-methoxybutane in Example 1 (2). (3R
* , 4S * , 5R * )-3-Hydroxy-3- (4-phenoxy-1-butyl) -4- [2- (3-methoxycarbonyl-1-propyl) phenyl] -5- (tert-
(Butyldimethylsiloxy) -1-cyclopentene was obtained.
【0081】1H−NMR(CDCl3,300MHz)
δppm;−0.24(s,3H),−0.14(s,
3H),0.78(s,9H),1.16−2.18
(m,9H),2.37(t,J=7.3Hz,2
H),2.51−2.65(m,1H),2.73−
2.88(m,1H),3.38(d,J=5.6H
z,1H),3.66(s,3H),3.95(d,J
=6.3Hz,2H),5.05−5.12(m,1
H),5.99(dd,J=5.8,1.2Hz,1
H),6.06(dd,J=5.8,1.6Hz,1
H),6.80−6.96(m,3H),7.11−
7.44(m,6H) IR(neat):3468,3059,3027,2
930,2857,1739,1601,1587,1
496,1472,1436,1412,1363,1
340,1301,1249,1173,1151,1
107,1076,994,941,881,838,
778,754,693,669,578,512 c
m-1 MS(FAB)(+KI)m/z:577(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; -0.24 (s, 3H), -0.14 (s,
3H), 0.78 (s, 9H), 1.16-2.18
(M, 9H), 2.37 (t, J = 7.3 Hz, 2
H), 2.51-2.65 (m, 1H), 2.73-
2.88 (m, 1H), 3.38 (d, J = 5.6H)
z, 1H), 3.66 (s, 3H), 3.95 (d, J
= 6.3 Hz, 2H), 5.05-5.12 (m, 1
H), 5.99 (dd, J = 5.8, 1.2 Hz, 1
H), 6.06 (dd, J = 5.8, 1.6 Hz, 1
H), 6.80-6.96 (m, 3H), 7.11-
7.44 (m, 6H) IR (neat): 3468, 3059, 3027, 2
930, 2857, 1739, 1601, 1587, 1
496, 1472, 1436, 1412, 1363, 1
340,1301,1249,1173,1151,1
107, 1076, 994, 941, 881, 838,
778, 754, 693, 669, 578, 512 c
m -1 MS (FAB) (+ KI) m / z: 577 (MK + ).
【0082】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして(3R*,4S*,5
R*)−3−(4−フェノキシ−1−ブチル)−4−
[2−(3−メトキシカルボニル−1−プロピル)フェ
ニル]−3,5−ジヒドロキシ−1−シクロペンテンを
得た。(2) Using the compound obtained in the above (1), (3R * , 4S * , 5) was prepared in substantially the same manner as in Example 1 (3).
R * )-3- (4-Phenoxy-1-butyl) -4-
[2- (3-Methoxycarbonyl-1-propyl) phenyl] -3,5-dihydroxy-1-cyclopentene was obtained.
【0083】1H−NMR(CDCl3,300MHz)
δppm;1.43−2.08(m,9H),2.39
(t,J=6.7Hz,2H),2.48−2.63
(m,1H),2.71(d,J=5.6Hz,1
H),3.45(d,J=5.3Hz,1H),3.5
4(s,3H),3.95(t,J=6.3Hz,1
H),5.06−5.14(m,1H),6.04(d
d,J=5.8,1.3Hz,1H),6.18(d
d,J=5.8,1.7Hz,1H),6.81−7.
00(m,3H),7.15−7.42(m,6H)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.43-2.08 (m, 9H), 2.39
(T, J = 6.7 Hz, 2H), 2.48-2.63
(M, 1H), 2.71 (d, J = 5.6 Hz, 1
H), 3.45 (d, J = 5.3 Hz, 1H), 3.5
4 (s, 3H), 3.95 (t, J = 6.3 Hz, 1
H), 5.06-5.14 (m, 1H), 6.04 (d
d, J = 5.8, 1.3 Hz, 1H), 6.18 (d
d, J = 5.8, 1.7 Hz, 1H), 6.81-7.
00 (m, 3H), 7.15-7.42 (m, 6H).
【0084】(3)上記(2)で得た化合物を用い、実
施例1(4)と実質的に同様にして標記化合物を得た。(3) Using the compound obtained in the above (2), the title compound was obtained in substantially the same manner as in Example 1 (4).
【0085】1H−NMR(CDCl3,300MHz)
δppm;1.50−2.09(m,8H),1.77
(s,1H),2.39(t,J=6.8Hz,1
H),2.55−2.88(m,2H),3.63
(s,3H),4.00(t,J=6.4Hz,2
H),4.02(s,1H),6.41(d,J=5.
8Hz,1H),6.82−7.00(m,4H),
7.13−7.35(m,5H),7.65(d,J=
5.8Hz,1H) IR(neat):3468,3062,3027,2
948,2872,1943,1714,1600,1
587,1495,1471,1436,1417,1
368,1337,1293,1245,1174,1
149,1081,1034,952,884,83
8,757,694,645,587,514 cm-1 MS(FAB)m/z:423(MH+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.50-2.09 (m, 8H), 1.77
(S, 1H), 2.39 (t, J = 6.8 Hz, 1
H), 2.55-2.88 (m, 2H), 3.63.
(S, 3H), 4.00 (t, J = 6.4 Hz, 2
H), 4.02 (s, 1H), 6.41 (d, J = 5.
8Hz, 1H), 6.82-7.00 (m, 4H),
7.13-7.35 (m, 5H), 7.65 (d, J =
5.8 Hz, 1 H) IR (neat): 3468, 3062, 3027, 2
948,2872,1943,1714,1600,1
587, 1495, 1471, 1436, 1417, 1
368, 1337, 1293, 1245, 1174, 1
149, 1081, 1034, 952, 884, 83
8,757,694,645,587,514 cm -1 MS (FAB) m / z: 423 (MH <+> ).
【0086】実施例6(4R*,5R*)−4−ヒドロキシ−4−(4−フェノ
キシ−1−ブチル)−5−[2−(4−メトキシ−1−
ブチル)フェニル]−2−シクロペンテン−1−オン (1)実施例1(2)において、(4R*,5S*)−4
−(tert−ブチルジメチルシロキシ)−5−[2−
(3−メトキシカルボニル−1−プロピル)フェニル]
−2−シクロペンテン−1−オンの代わりに実施例2
(1)で得た(4R*,5S*)−4−(tert−ブチ
ルジメチルシロキシ)−5−[2−(4−メトキシ−1
−ブチル)フェニル]−2−シクロペンテン−1−オン
を、4−ブロモ−1−メトキシブタンの代わりに4−ブ
ロモ−1−フェノキシブタンを用い、実施例1(2)と
実質的に同様にして(3S*,4S*,5R*)−3−ヒ
ドロキシ−3−(4−フェノキシ−1−ブチル)−4−
[2−(4−メトキシ−1−ブチル)フェニル]−5−
(tert−ブチルジメチルシロキシ)−1−シクロペ
ンテンおよび(3R*,4S*,5R*)−3−ヒドロキ
シ−3−(4−フェノキシ−1−ブチル)−4−[2−
(4−メトキシ−1−ブチル)フェニル]−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン
を得た。Example 6 (4R * , 5R * )-4-hydroxy-4- (4-pheno)
Xy-1-butyl) -5- [2- (4-methoxy-1-
Butyl) phenyl] -2-cyclopenten-1-one (1) In Example 1 (2), (4R * , 5S * )-4
-(Tert-butyldimethylsiloxy) -5- [2-
(3-methoxycarbonyl-1-propyl) phenyl]
Example 2 Instead of -2-cyclopenten-1-one
(4R * , 5S * )-4- (tert-butyldimethylsiloxy) -5- [2- (4-methoxy-1) obtained in (1)
-Butyl) phenyl] -2-cyclopenten-1-one was prepared in substantially the same manner as in Example 1 (2) using 4-bromo-1-phenoxybutane instead of 4-bromo-1-methoxybutane. (3S * , 4S * , 5R * )-3-hydroxy-3- (4-phenoxy-1-butyl) -4-
[2- (4-Methoxy-1-butyl) phenyl] -5-
(Tert-butyldimethylsiloxy) -1-cyclopentene and (3R * , 4S * , 5R * )-3-hydroxy-3- (4-phenoxy-1-butyl) -4- [2-
(4-methoxy-1-butyl) phenyl] -5- (te
(rt-butyldimethylsiloxy) -1-cyclopentene was obtained.
【0087】(3S*,4S*,5R*)−3−ヒドロキ
シ−3−(4−フェノキシ−1−ブチル)−4−[2−
(4−メトキシ−1−ブチル)フェニル]−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン 1 H−NMR(CDCl3,300MHz)δppm;−
0.22(s,3H),−0.07(s,3H),0.
80(s,9H),1.18−1.82(m,10
H),2.26(s,1H),2.51−2.67
(m,1H),2.89−3.02(m,1H),3.
32(s,3H),3.35−3.47(m,2H),
3.58(d,J=5.4Hz,1H),3.82
(t,J=6.3Hz,2H),4.85−4.90
(m,1H),5.95(dd,J=5.7,1.7H
z,1H),6.05(dd,J=5.7,0.8H
z,1H),6.79−6.95(m,3H),7.1
0−7.30(m,6H) IR(neat):3436,3059,2930,2
858,1601,1587,1497,1472,1
388,1363,1301,1248,1172,1
107,1080,1036,993,941,88
2,864,837,778,753,692,67
2,512 cm-1 MS(FAB)(+KI)m/z:563(MK+)。 (3S * , 4S * , 5R * )-3-hydroxy
C-3- (4-phenoxy-1-butyl ) -4- [2-
(4-methoxy-1-butyl) phenyl] -5- (te
rt-butyldimethylsiloxy) -1-cyclopentene 1 H-NMR (CDCl 3 , 300 MHz) δ ppm;
0.22 (s, 3H), -0.07 (s, 3H), 0.
80 (s, 9H), 1.18-1.82 (m, 10
H), 2.26 (s, 1H), 2.51-2.67.
(M, 1H), 2.89-3.02 (m, 1H), 3.
32 (s, 3H), 3.35-3.47 (m, 2H),
3.58 (d, J = 5.4 Hz, 1H), 3.82
(T, J = 6.3 Hz, 2H), 4.85-4.90
(M, 1H), 5.95 (dd, J = 5.7, 1.7H
z, 1H), 6.05 (dd, J = 5.7, 0.8H
z, 1H), 6.79-6.95 (m, 3H), 7.1
0-7.30 (m, 6H) IR (neat): 3436, 3059, 2930, 2
858, 1601, 1587, 1497, 1472, 1
388, 1363, 1301, 1248, 1172, 1
107, 1080, 1036, 993, 941, 88
2,864,837,778,753,692,67
2,512 cm -1 MS (FAB) (+ KI) m / z: 563 (MK + ).
【0088】(3R*,4S*,5R*)−3−ヒドロキ
シ−3−(4−フェノキシ−1−ブチル)−4−[2−
(4−メトキシ−1−ブチル)フェニル]−5−(te
rt−ブチルジメチルシロキシ)−1−シクロペンテン 1 H−NMR(CDCl3,300MHz)δppm;−
0.23(s,3H),−0.14(s,3H),0.
79(s,9H),1.35−1.95(m,11
H),2.49−2.83(m,2H),3.30−
3.45(m,3H),3.31(s,3H),3.9
1(s,1H),3.95(t,J=6.3Hz,2
H),5.05−5.12(m,1H),5.99(d
d,J=5.8,1.1Hz,1H),6.06(d
d,J=5.8,1.6Hz,1H),6.83−6.
97(m,3H),7.17−7.41(m,6H) IR(neat):3436,3059,2928,2
858,1601,1587,1497,1471,1
411,1388,1362,1341,1300,1
247,1172,1119,1077,1007,9
40,882,837,778,753,692 cm
-1 MS(FAB)(+KI)m/z:563(MK+)。 (3R * , 4S * , 5R * )-3-hydroxy
C-3- (4-phenoxy-1-butyl ) -4- [2-
(4-methoxy-1-butyl) phenyl] -5- (te
rt-butyldimethylsiloxy) -1-cyclopentene 1 H-NMR (CDCl 3 , 300 MHz) δ ppm;
0.23 (s, 3H), -0.14 (s, 3H), 0.
79 (s, 9H), 1.35-1.95 (m, 11
H), 2.49-2.83 (m, 2H), 3.30-
3.45 (m, 3H), 3.31 (s, 3H), 3.9
1 (s, 1H), 3.95 (t, J = 6.3 Hz, 2
H), 5.05-5.12 (m, 1H), 5.99 (d
d, J = 5.8, 1.1 Hz, 1H), 6.06 (d
d, J = 5.8, 1.6 Hz, 1H), 6.83-6.
97 (m, 3H), 7.17-7.41 (m, 6H) IR (neat): 3436, 3059, 2928, 2
858, 1601, 1587, 1497, 1471, 1
411, 1388, 1362, 1341, 1300, 1
247, 1172, 1119, 1077, 1007, 9
40,882,837,778,753,692 cm
-1 MS (FAB) (+ KI) m / z: 563 (MK + ).
【0089】(2)上記(1)で得た(3R*,4S*,
5R*)−3−ヒドロキシ−3−(4−フェノキシ−1
−ブチル)−4−[2−(4−メトキシ−1−ブチル)
フェニル]−5−(tert−ブチルジメチルシロキ
シ)−1−シクロペンテンを用い、実施例1(3)と実
質的に同様にして(3R*,4S*,5R*)−3−(4
−フェノキシ−1−ブチル)−4−[2−(4−メトキ
シ−1−ブチル)フェニル]−3,5−ジヒドロキシ−
1−シクロペンテンを得た。(2) (3R * , 4S * ,
5R * )-3-Hydroxy-3- (4-phenoxy-1
-Butyl) -4- [2- (4-methoxy-1-butyl)
(3R * , 4S * , 5R * )-3- (4) using substantially [phenyl] -5- (tert-butyldimethylsiloxy) -1-cyclopentene in the same manner as in Example 1 (3).
-Phenoxy-1-butyl) -4- [2- (4-methoxy-1-butyl) phenyl] -3,5-dihydroxy-
1-Cyclopentene was obtained.
【0090】1H−NMR(CDCl3,300MHz)
δppm;1.51−1.86(m,11H),2.3
5(d,J=6.3Hz,1H),2.48−2.63
(m,1H),2.77−2.92(m,1H),3.
25−3.46(m,3H),3.28(s,3H),
3.95(t,J=6.2Hz,2H),5.04−
5.12(m,1H),6.04(dd,J=5.8,
1.2Hz,1H),6.15(dd,J=5.8,
1.8Hz,1H),6.83−6.98(m,3
H),7.18−7.40(m,6H)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.51-1.86 (m, 11H), 2.3
5 (d, J = 6.3 Hz, 1H), 2.48-2.63
(M, 1H), 2.77-2.92 (m, 1H), 3.
25-3.46 (m, 3H), 3.28 (s, 3H),
3.95 (t, J = 6.2 Hz, 2H), 5.04-
5.12 (m, 1H), 6.04 (dd, J = 5.8,
1.2 Hz, 1 H), 6.15 (dd, J = 5.8,
1.8 Hz, 1 H), 6.83-6.98 (m, 3
H), 7.18-7.40 (m, 6H).
【0091】(3)上記(2)で得た化合物を用い、実
施例1(4)と実質的に同様にして標記化合物を得た。(3) Using the compound obtained in the above (2), the title compound was obtained in substantially the same manner as in Example 1 (4).
【0092】1H−NMR(CDCl3,300MHz)
δppm;1.52−2.07(m,10H),1.7
2(s,1H),2.58−2.81(m,2H),
3.31(s,3H),3.38(t,J=6.0H
z,2H),3.95(s,1H),3.99(t,J
=6.2Hz,1H),6.41(t,J=5.8H
z,2H),6.81−6.98(m,4H),7.1
3−7.34(m,5H),7.65(d,J=5.8
Hz,1H) IR(neat):3436,3062,3027,2
943,2871,1713,1600,1587,1
495,1472,1390,1336,1293,1
245,1173,1117,1082,1032,9
48,885,838,801,755,693,64
4,587,513 cm-1 MS(FAB)m/z:409(MH+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.52-2.07 (m, 10H), 1.7
2 (s, 1H), 2.58-2.81 (m, 2H),
3.31 (s, 3H), 3.38 (t, J = 6.0H)
z, 2H), 3.95 (s, 1H), 3.99 (t, J
= 6.2 Hz, 1H), 6.41 (t, J = 5.8H)
z, 2H), 6.81-6.98 (m, 4H), 7.1.
3-7.34 (m, 5H), 7.65 (d, J = 5.8)
Hz, 1H) IR (neat): 3436, 3062, 3027, 2
943,2871, 1713,1600,1587,1
495, 1472, 1390, 1336, 1293, 1
245, 1173, 1117, 1082, 1032, 9
48,885,838,801,755,693,64
4,587,513 cm -1 MS (FAB) m / z: 409 (MH <+> ).
【0093】実施例7(4R*,5R*)−4−ヒドロキシ−4−(4−フェノ
キシ−1−ブチル)−5−[2−(4−ヒドロキシ−1
−ブチル)フェニル]−2−シクロペンテン−1−オン (1)実施例1(2)において、(4R*,5S*)−4
−(tert−ブチルジメチルシロキシ)−5−[2−
(3−メトキシカルボニル−1−プロピル)フェニル]
−2−シクロペンテン−1−オンの代わりに実施例3
(1)で得た(4R*,5S*)−4−(tert−ブチ
ルジメチルシロキシ)−5−[2−(4−tert−ブ
トキシ−1−ブチル)フェニル]−2−シクロペンテン
−1−オンを、4−ブロモ−1−メトキシブタンの代わ
りに4−ブロモ−1−フェノキシブタンを用い、実施例
1(2)と実質的に同様にして(3RS,4S*,5
R*)−3−ヒドロキシ−3−(4−フェノキシ−1−
ブチル)−4−[2−(4−tert−ブチルジメチル
シロキシ−1−ブチル)フェニル]−5−(tert−
ブチルジメチルシロキシ)−1−シクロペンテンを得
た。Example 7 (4R * , 5R * )-4-hydroxy-4- (4-pheno)
Xy-1-butyl) -5- [2- (4-hydroxy-1
-Butyl) phenyl] -2-cyclopenten-1-one (1) In Example 1 (2), (4R * , 5S * )-4
-(Tert-butyldimethylsiloxy) -5- [2-
(3-methoxycarbonyl-1-propyl) phenyl]
Example 3 in place of -2-cyclopenten-1-one
(4R * , 5S * )-4- (tert-butyldimethylsiloxy) -5- [2- (4-tert-butoxy-1-butyl) phenyl] -2-cyclopenten-1-one obtained in (1). Was prepared in substantially the same manner as in Example 1 (2) using 4-bromo-1-phenoxybutane instead of 4-bromo-1-methoxybutane (3RS, 4S * , 5).
R * )-3-Hydroxy-3- (4-phenoxy-1-
Butyl) -4- [2- (4-tert-butyldimethylsiloxy-1-butyl) phenyl] -5- (tert-
(Butyldimethylsiloxy) -1-cyclopentene was obtained.
【0094】1H−NMR(CDCl3,200MHz)
δppm;−0.24,−0.21,−0.15,−
0.07 and 0.05(5s, 12H),0.
75(s,9H),0.89(s,9H),1.16−
2.06(m,11H),2.44−2.85(m,2
H),3.37−3.67(m,3H),3.76−
3.98(m,2H),4.83−5.10(m,1
H),5.93−6.08(m,2H),6.76−
7.41(m,9H) IR(neat):3436,3060,2931,1
923,1728,1602,1588,1497,1
472,1387,1362,1301,1250,1
172,1104,1006,940,882,83
7,777,753,692,667,578,511
cm-1 MS(FAB)(+KI)m/z:663(MK+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; -0.24, -0.21, -0.15,-
0.07 and 0.05 (5s, 12H), 0.
75 (s, 9H), 0.89 (s, 9H), 1.16
2.06 (m, 11H), 2.44-2.85 (m, 2
H), 3.37-3.67 (m, 3H), 3.76-
3.98 (m, 2H), 4.83-5.10 (m, 1
H), 5.93-6.08 (m, 2H), 6.76-
7.41 (m, 9H) IR (neat): 3436, 3060, 2931, 1
923, 1728, 1602, 1588, 1497, 1
472, 1387, 1362, 1301, 1250, 1
172, 1104, 1006, 940, 882, 83
7,777,753,692,667,578,511
cm -1 MS (FAB) (+ KI) m / z: 663 (MK + ).
【0095】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして(3R*,4S*,5
R*)−3−(4−フェノキシブチル)−4−[2−
(4−ヒドロキシ−1−ブチル)フェニル]−3,5−
ジヒドロキシ−1−シクロペンテンを得た。(2) Using the compound obtained in the above (1), (3R * , 4S * , 5) was prepared in substantially the same manner as in Example 1 (3).
R * )-3- (4-phenoxybutyl) -4- [2-
(4-hydroxy-1-butyl) phenyl] -3,5-
Dihydroxy-1-cyclopentene was obtained.
【0096】1H−NMR(CDCl3,300MHz)
δppm;1.20−1.88(m,12H),2.2
6(t,J=5.9Hz,1H),2.51−2.63
(m,1H),2.80−2.92(m,1H),3.
43(d,J=5.1Hz,1H),3.54−3.7
4(m,2H),3.97(t,J=6.2Hz,1
H),5.07−5.14(m,1H),6.05(d
d,J=5.8,1.2Hz,1H),6.15(d
d,J=5.8,1.9Hz,1H),6.84−6.
98(m,3H),7.20−7.39(m,6H) IR(neat):3368,3059,2939,2
871,1724,1601,1587,1496,1
472,1392,1302,1246,1173,1
104,1060,1034,755,693,512
cm-1 (3)上記(2)で得た化合物を用い、実施例1(4)
と実質的に同様にして標記化合物を得た。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.20-1.88 (m, 12H), 2.2
6 (t, J = 5.9 Hz, 1H), 2.51-2.63
(M, 1H), 2.80-2.92 (m, 1H), 3.
43 (d, J = 5.1 Hz, 1H), 3.54-3.7
4 (m, 2H), 3.97 (t, J = 6.2 Hz, 1
H), 5.07-5.14 (m, 1H), 6.05 (d
d, J = 5.8, 1.2 Hz, 1H), 6.15 (d
d, J = 5.8, 1.9 Hz, 1H), 6.84-6.
98 (m, 3H), 7.20-7.39 (m, 6H) IR (neat): 3368, 3059, 2939, 2
871, 1724, 1601, 1587, 1496, 1
472, 1392, 1302, 1246, 1173, 1
104,1060,1034,755,693,512
cm -1 (3) Using the compound obtained in the above (2), Example 1 (4)
The title compound was obtained in substantially the same manner as described above.
【0097】1H−NMR(CDCl3,300MHz)
δppm;1.38−2.10(m,12H),2.5
5−2.86(m,2H),3.60(t,J=6.2
Hz,1H),3.97(s,1H),3.99(t,
J=6.1Hz,2H),6.41(d,J=5.8H
z,1H),6.74−7.00(m,4H),7.1
2−7.36(m,5H),7.64(d,J=5.8
Hz,1H) IR(neat):3403,3062,2939,2
869,1708,1600,1587,1495,1
472,1392,1337,1293,1246,1
174,1152,1067,1032,951,88
3,795,756,694,587,514 cm-1 MS(FAB)(+KI)m/z:433(MK+)。 1 H-NMR (CDCl 3 , 300 MHz)
δ ppm; 1.38-2.10 (m, 12H), 2.5
5-2.86 (m, 2H), 3.60 (t, J = 6.2)
Hz, 1H), 3.97 (s, 1H), 3.99 (t,
J = 6.1 Hz, 2H), 6.41 (d, J = 5.8H)
z, 1H), 6.74-7.00 (m, 4H), 7.1
2-7.36 (m, 5H), 7.64 (d, J = 5.8)
Hz, 1H) IR (neat): 3403, 3062, 2939, 2
869, 1708, 1600, 1587, 1495, 1
472,1392,1337,1293,1246,1
174,1152,1067,1032,951,88
3,795,756,694,587,514 cm- 1 MS (FAB) (+ KI) m / z: 433 (MK + ).
【0098】実施例8(4R*,5R*)−4−ヒドロキシ−4−(4−フェノ
キシ−1−ブチル)−5−フェニル−2−シクロペンテ
ン−1−オン (1)実施例1(2)において、(4R*,5S*)−4
−(tert−ブチルジメチルシロキシ)−5−[2−
(3−メトキシカルボニル−1−プロピル)フェニル]
−2−シクロペンテン−1−オンの代わりに参考例2で
得た(4R*,5S*)−5−フェニル−4−(tert
ーブチルジメチルシロキシ)−2−シクロペンテン−1
−オンを用い、4−ブロモ−1−メトキシブタンの代わ
りに4−ブロモ−1−フェノキシブタンを用い、実施例
1(2)と実質的に同様にして(3RS,4S*,5
R*)−3−ヒドロキシ−3−(4−フェノキシ−1−
ブチル)−4−フェニル−5−(tert−ブチルジメ
チルシロキシ)−1−シクロペンテンを得た。Example 8 (4R * , 5R * )-4-hydroxy-4- (4-pheno)
(Xy-1-butyl) -5-phenyl-2-cyclopente
Down-1-one (1) Example 1 in (2), (4R *, 5S *) -4
-(Tert-butyldimethylsiloxy) -5- [2-
(3-methoxycarbonyl-1-propyl) phenyl]
(4R * , 5S * )-5-phenyl-4- (tert) obtained in Reference Example 2 instead of -2-cyclopenten-1-one
-Butyldimethylsiloxy) -2-cyclopentene-1
And using 4-bromo-1-phenoxybutane instead of 4-bromo-1-methoxybutane in substantially the same manner as in Example 1 (2) (3RS, 4S * , 5
R * )-3-Hydroxy-3- (4-phenoxy-1-
(Butyl) -4-phenyl-5- (tert-butyldimethylsiloxy) -1-cyclopentene was obtained.
【0099】1H−NMR(CDCl3,200MHz)
δppm;−0.23(s,3H),−0.13(s,
3H),0.77(s,9H),1.42−1.87
(m,7H),3.00(d,J=5.7Hz,1
H),3.95(t,J=6.2Hz,2H),5.1
6(dd,J=5.9Hz,1H),5.92−6.0
7(m,2H),6.77−6.98(m,4H),
7.16−7.47(m,6H) IR(neat):3436,3060,3030,2
952,2930,2857,1754,1709,1
601,1587,1497,1472,1388,1
362,1301,1248,1172,1113,1
080,1034,993,940,883,866,
837,778,754,693,512cm-1 MS(FAB)(+KI)m/z:477(MK+)。 1 H-NMR (CDCl 3 , 200 MHz)
δ ppm; −0.23 (s, 3H), −0.13 (s,
3H), 0.77 (s, 9H), 1.42-1.87.
(M, 7H), 3.00 (d, J = 5.7 Hz, 1
H), 3.95 (t, J = 6.2 Hz, 2H), 5.1
6 (dd, J = 5.9 Hz, 1H), 5.92-6.0
7 (m, 2H), 6.77-6.98 (m, 4H),
7.16-7.47 (m, 6H) IR (neat): 3436, 3060, 3030, 2
952, 2930, 2857, 1754, 1709, 1
601, 1587, 1497, 1472, 1388, 1
362, 1301, 1248, 1172, 1113, 1
080, 1034, 993, 940, 883, 866,
837, 778, 754, 693, 512 cm -1 MS (FAB) (+ KI) m / z: 477 (MK + ).
【0100】(2)上記(1)で得た化合物を用い、実
施例1(3)と実質的に同様にして(3S*,4S*,5
R*)−3,5−ジヒドロキシ−3−(4−フェノキシ
−1−ブチル)−4−フェニル−1−シクロペンテンお
よび(3R*,4S*,5R*)−3,5−ジヒドロキシ
−3−(4−フェノキシ−1−ブチル)−4−フェニル
−1−シクロペンテンを得た。(2) Using the compound obtained in the above (1), (3S * , 4S * , 5) was obtained in substantially the same manner as in Example 1 (3).
R * )-3,5-dihydroxy-3- (4-phenoxy-1-butyl) -4-phenyl-1-cyclopentene and (3R * , 4S * , 5R * )-3,5-dihydroxy-3- ( 4-Phenoxy-1-butyl) -4-phenyl-1-cyclopentene was obtained.
【0101】(3S*,4S*,5R*)−3,5−ジヒ
ドロキシ−3−(4−メトキシ−1−ブチル)−4−フ
ェニル−1−シクロペンテン 1 H−NMR(CDCl3,300MHz)δppm;
1.10−2.08(m,8H),3.22(d,J=
6.6Hz,1H),3.80(t,J=6.1Hz,
2H),4.99−5.08(m,1H),5.99−
6.16(m,2H),6.78−6.95(m,3
H),7.21−7.38(m,7H) IR(neat):3338,3060,3030,2
950,2871,1600,1587,1498,1
470,1455,1387,1339,1302,1
245,1173,1103,1081,1069,1
035,1005,970,944,882,819,
759,693,652 cm-1 MS(FAB)(+KI)m/z:363(MK+)。 (3S * , 4S * , 5R * )-3,5-dihi
Droxy-3- (4-methoxy-1-butyl) -4-f
Phenyl- 1 -cyclopentene 1 H-NMR (CDCl 3 , 300 MHz) δ ppm;
1.10-2.08 (m, 8H), 3.22 (d, J =
6.6 Hz, 1 H), 3.80 (t, J = 6.1 Hz,
2H), 4.99-5.08 (m, 1H), 5.99-
6.16 (m, 2H), 6.78-6.95 (m, 3
H), 7.21-7.38 (m, 7H) IR (neat): 3338, 3060, 3030, 2
950,2871,1600,1587,1498,1
470, 1455, 1387, 1339, 1302, 1
245, 1173, 1103, 1081, 1069, 1
035, 1005, 970, 944, 882, 819,
759, 693, 652 cm -1 MS (FAB) (+ KI) m / z: 363 (MK + ).
【0102】(3R*,4S*,5R*)−3,5−ジヒ
ドロキシ−3−(4−メトキシ−1−ブチル)−4−フ
ェニル−1−シクロペンテン 1 H−NMR(CDCl3,200MHz)δppm;
1.08−2.22(m,8H),3.02(d,J=
6.2Hz,1H),3.96(t,J=6.3Hz,
2H),5.16−5.28(m,1H),5.98
(dd,J=5.7,1.4Hz,1H),6.12
(dd,J=5.7,1.7Hz,1H),6.75−
7.00(m,3H),7.18−7.40(m,7
H) IR(neat):3369,3058,2943,2
870,1600,1586,1496,1473,1
454,1391,1301,1246,1173,1
105,1080,1033,982,882,77
3,755,693,513 cm-1 MS(FAB)(+KI)m/z:363(MK+)。 (3R * , 4S * , 5R * )-3,5-dihi
Droxy-3- (4-methoxy-1-butyl) -4-f
Phenyl- 1 -cyclopentene 1 H-NMR (CDCl 3 , 200 MHz) δ ppm;
1.08-2.22 (m, 8H), 3.02 (d, J =
6.2 Hz, 1 H), 3.96 (t, J = 6.3 Hz,
2H), 5.16-5.28 (m, 1H), 5.98
(Dd, J = 5.7, 1.4 Hz, 1H), 6.12
(Dd, J = 5.7, 1.7 Hz, 1H), 6.75 −
7.00 (m, 3H), 7.18-7.40 (m, 7
H) IR (neat): 3369, 3058, 2943, 2
870, 1600, 1586, 1496, 1473, 1
454, 1391, 1301, 1246, 1173, 1
105, 1080, 1033, 982, 882, 77
3,755,693,513 cm -1 MS (FAB) (+ KI) m / z: 363 (MK + ).
【0103】(3)上記(2)で得た(3R*,4S*,
5R*)−3,5−ジヒドロキシ−3−(4−メトキシ
−1−ブチル)−4−フェニル−1−シクロペンテンを
用い、実施例1(4)と実質的に同様にして標記化合物
を得た。(3) (3R * , 4S * ,
Using 5R * )-3,5-dihydroxy-3- (4-methoxy-1-butyl) -4-phenyl-1-cyclopentene, the title compound was obtained in substantially the same manner as in Example 1 (4). .
【0104】1H−NMR(CDCl3,400MHz)
δppm;1.55(br s,1H),1.62−
1.75(m,2H),1.80−1.97(m,4
H),3.66(s,1H),3.99(t,J=6.
2Hz,2H),6.37(d,J=5.9Hz,1
H),6.86−6.97(m,3H),7.06−
7.12(m,2H),7.23−7.40(m,5
H),7.60(d,J=5.9Hz,1H) IR(neat):3441,3062,3030,2
943,2870,1713,1600,1587,1
497,1473,1454,1391,1338,1
293,1246,1173,1081,1034,8
83,798,756,695,601,514,48
7 cm-1 MS(FAB)(+KI)m/z:361(MK+)。 1 H-NMR (CDCl 3 , 400 MHz)
δ ppm; 1.55 (brs, 1H), 1.62-
1.75 (m, 2H), 1.80-1.97 (m, 4
H), 3.66 (s, 1H), 3.99 (t, J = 6.
2 Hz, 2H), 6.37 (d, J = 5.9 Hz, 1
H), 6.86-6.97 (m, 3H), 7.06-
7.12 (m, 2H), 7.23-7.40 (m, 5
H), 7.60 (d, J = 5.9 Hz, 1H) IR (neat): 3441, 3062, 3030, 2
943,2870,1713,1600,1587,1
497, 1473, 1454, 1391, 1338, 1
293,1246,1173,1081,1034,8
83,798,756,695,601,514,48
7 cm -1 MS (FAB) (+ KI) m / z: 361 (MK + ).
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI C07C 69/738 C07C 69/738 Z 323/22 323/22 323/52 323/52 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI C07C 69/738 C07C 69/738 Z 323/22 323/22 323/52 323/52
Claims (7)
素原子または式 −CO2R4 (式中、R4は水素原子、炭素数1〜5のアルキル基ま
たは炭素数2〜6のアルケニル基を示す。)で表される
基を示し、nは0または1を示し、m,pはそれぞれ0
〜5の整数を示す。}で表される基を示し、R2は式 −(CH2)qY2 rR5 (式中、Y2は酸素原子または硫黄原子を示し、R5は水
素原子、炭素数1〜5のアルキル基、炭素数2〜6のア
ルケニル基、炭素数2〜6のアルキニル基、炭素数3〜
7のシクロアルキル基またはアリール基を示し、rは0
または1を示し、qは0〜5の整数を示す。)で表され
る基を示す。Xは水素原子または水酸基を示す。]で表
されるフェニル置換ヒドロキシシクロペンテノン類縁体
またはその製薬学的に許容される塩。1. A compound of the formula (I) [Wherein, R 1 represents a halogen atom or a formula — (CH 2 ) m Y 1 n (CH 2 ) p R 3 }, wherein Y 1 represents an oxygen atom or a sulfur atom, and R 3 represents a hydrogen atom or a formula CO 2 R 4 (wherein R 4 represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms or an alkenyl group having 2 to 6 carbon atoms), and n represents 0 or 1. , M and p are each 0
Represents an integer of from 5 to 5. Wherein R 2 is a group represented by the formula — (CH 2 ) q Y 2 r R 5 (wherein Y 2 represents an oxygen atom or a sulfur atom, R 5 is a hydrogen atom, and has 1 to 5 carbon atoms). Alkyl group, alkenyl group having 2 to 6 carbon atoms, alkynyl group having 2 to 6 carbon atoms,
7 represents a cycloalkyl group or an aryl group, and r represents 0
Or 1 and q represents an integer of 0 to 5; ). X represents a hydrogen atom or a hydroxyl group. A phenyl-substituted hydroxycyclopentenone analog or a pharmaceutically acceptable salt thereof.
基である。)で示される基であり、pは0または1であ
る。}で示される基であり、R5が水素原子、炭素数1
〜5のアルキル基、炭素数2〜6のアルケニル基、炭素
数2〜6のアルキニル基、炭素数5〜7のシクロアルキ
ル基またはアリール基である請求項1に記載のフェニル
置換ヒドロキシシクロペンテノン類縁体またはその製薬
学的に許容される塩。Wherein R 1 has the formula - (CH 2) m Y 1 n (CH 2) p R 3 { wherein, R 3 is a hydrogen atom or the formula -CO 2 R 4 (wherein, R 4 is a hydrogen atom Or an alkyl group having 1 to 5 carbon atoms), and p is 0 or 1. And R 5 is a hydrogen atom, having 1 carbon atom
The phenyl-substituted hydroxycyclopentenone according to claim 1, which is an alkyl group having 5 to 5 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, a cycloalkyl group or an aryl group having 5 to 7 carbon atoms. An analog or a pharmaceutically acceptable salt thereof.
シカルボニル基またはエトキシカルボニル基であり、R
5が水素原子、炭素数1〜5のアルキル基、炭素数5〜
7のシクロアルキル基またはフェニル基である請求項2
に記載のフェニル置換ヒドロキシシクロペンテノン類縁
体またはその製薬学的に許容される塩。(3) R 3 is a hydrogen atom, a carboxyl group, a methoxycarbonyl group or an ethoxycarbonyl group;
5 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, 5 to 5 carbon atoms
7. A cycloalkyl group or a phenyl group of 7.
Or a pharmaceutically acceptable salt thereof.
る請求項1〜3のいずれかに記載のフェニル置換ヒドロ
キシシクロペンテノン類縁体またはその製薬学的に許容
される塩。4. The phenyl-substituted hydroxycyclopentenone analog or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y 1 is an oxygen atom and Y 2 is an oxygen atom.
かに記載のフェニル置換ヒドロキシシクロペンテノン類
縁体またはその製薬学的に許容される塩。5. The phenyl-substituted hydroxycyclopentenone analog or a pharmaceutically acceptable salt thereof according to claim 1, wherein X is a hydrogen atom.
たはその製薬学的に許容される塩を含有することを特徴
とする医薬組成物。6. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
組成物。7. The pharmaceutical composition according to claim 6, which is an osteogenesis promoter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9201841A JPH1143460A (en) | 1997-07-28 | 1997-07-28 | Phenyl-substituted hydroxycyclopentenone analogue |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9201841A JPH1143460A (en) | 1997-07-28 | 1997-07-28 | Phenyl-substituted hydroxycyclopentenone analogue |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH1143460A true JPH1143460A (en) | 1999-02-16 |
Family
ID=16447789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9201841A Withdrawn JPH1143460A (en) | 1997-07-28 | 1997-07-28 | Phenyl-substituted hydroxycyclopentenone analogue |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH1143460A (en) |
-
1997
- 1997-07-28 JP JP9201841A patent/JPH1143460A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Danheiser et al. | Scope and stereochemical course of the addition of (trimethylsilyl) allenes to ketones and aldehydes. A regiocontrolled synthesis of homopropargylic alcohols | |
EP3231793B1 (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
HU221588B (en) | Vitamin d-25-carboxylic acid derivatives and pharmaceutical compositions containing them | |
Desrat et al. | Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins | |
CN101293894B (en) | Preparing intermediate of 2-propylidene-19-nor-vitamin D compounds | |
JP3507435B2 (en) | Cyclohexanediol derivative | |
EP3737470B9 (en) | 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists | |
US5500417A (en) | Arylmethylphosphonates and phosphonic acids useful as anti-inflammatory agents | |
US5349112A (en) | Cyclic anti-tumor promoter compounds, compositions and methods for production and use | |
JP6643308B2 (en) | Metal-catalyzed asymmetric 1,4-conjugate addition of vinyl boron compounds to 2-substituted-4-oxy-cyclopent-2-en-1-ones to yield prostaglandins and prostaglandin analogs | |
JPH1143460A (en) | Phenyl-substituted hydroxycyclopentenone analogue | |
EP0180399B1 (en) | Anti-tumor 4-hydroxy-2-cyclopentenones | |
Grieco et al. | Carbon-14 fluorinated prostaglandins: synthesis and biological evaluation of the methyl esters of (+)-14-fluoro-,(+)-15-epi-14-fluoro-,(+)-13 (E)-14-fluoro-, and (+)-13 (E)-15-epi-14-fluoroprostaglandin F2. alpha. | |
EP0133450B1 (en) | Conjugate addition of organocuprates generated from copper (i) cyanide and vinyl stannanes useful in prostaglandin analog synthesis | |
US5210237A (en) | Vitamin d3 analogues | |
AU2011321624B2 (en) | 23-yne-vitamin D3 derivative | |
US5072002A (en) | Synthesis of cholesterol-lowering agents | |
JPH1143459A (en) | Phenyl-substituted hydroxycyclopentenone analogue | |
EP0232776A2 (en) | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | |
US4054604A (en) | Amide derivatives of 9-oxo-13-trans-prostenoic acid | |
CN101068779B (en) | 9,10-secopregnane derivative and medicine | |
JPH0419223B2 (en) | ||
JPH1143461A (en) | Prostaglandin a1 analogue | |
JPH08208637A (en) | Prostaglandin i type compound, its intermediate, their production and blood platelet agglutination suppressant | |
US4293704A (en) | Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040727 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20070705 |